

Aus dem Zentrum für Augenheilkunde der Universität zu Köln
Klinik und Poliklinik für Allgemeine Augenheilkunde
Direktor: Universitätsprofessor Dr. med. Claus Cursiefen

Quantifizierung und Qualifizierung des Tumor Microenvironments beim uvealen Melanom

Inaugural-Dissertation zur Erlangung der Doktorwürde
der Medizinischen Fakultät
der Universität zu Köln

vorgelegt von
Lara Goesmann
aus Köln

promoviert am 22. März 2024

Dekan: Universitätsprofessor Dr. med. G. R. Fink
1. Gutachter: Universitätsprofessor Dr. med. Dr. phil. L. Heindl
2. Gutachter: Universitätsprofessor Dr. med. C. P. Pallasch

Erklärung

Ich erkläre hiermit, dass ich die vorliegende Dissertationsschrift ohne unzulässige Hilfe Dritter und ohne Benutzung anderer als der angegebenen Hilfsmittel angefertigt habe; die aus fremden Quellen direkt oder indirekt übernommenen Gedanken sind als solche kenntlich gemacht.

Bei der Auswahl und Auswertung des Materials habe ich Unterstützungsleistungen von folgenden Personen erhalten

Herr Univ.-Prof. Dr. Dr. Ludwig M. Heindl
Frau Dr. Nasrin Refaian

Weitere Personen waren an der Erstellung der vorliegenden Arbeit nicht beteiligt. Insbesondere habe ich nicht die Hilfe einer Promotionsberaterin/eines Promotionsberaters in Anspruch genommen. Dritte haben von mir weder unmittelbar noch mittelbar geldwerte Leistungen für Arbeiten erhalten, die im Zusammenhang mit dem Inhalt der vorgelegten Dissertationsschrift stehen.

Die Dissertationsschrift wurde von mir bisher weder im Inland noch im Ausland in gleicher oder ähnlicher Form einer anderen Prüfungsbehörde vorgelegt.

Die dieser Arbeit zugrunde liegenden Experimente sind von mir mit Unterstützung von Frau Dr. N. Refaian durchgeführt worden.

Die Studie beläuft sich auf uveale Melanome, welche im Zentrum für Augenheilkunde der Universität zu Köln zwischen 2007 und 2017 entnommen wurden.

Bei der statistischen Analyse, sowie der Visualisierung habe ich Unterstützung durch Frau Dr. N. Refaian erhalten.

Bei der Konzipierung der Veröffentlichung „Characterization and Quantitation of the Tumor Microenvironment of Uveal Melanoma“, welche im Mai 2023 im Journal *Biology* erschienen ist, haben Herr Univ.-Prof. Dr. Dr. Ludwig M. Heindl, Frau Dr. N. Refaian, Herr Dr. J. J. Bosch, Frau M. Becker, das Labor Univ.-Prof. Dr. A. Wodarz, Herr P. Zentis, Herr Dr. C. Jüngst und Herr Dr. K. Koch unterstützend mitgewirkt.

Die vorliegende Dissertationsschrift wurde vollständig von mir selbst angefertigt.

Erklärung zur guten wissenschaftlichen Praxis:

Ich erkläre hiermit, dass ich die Ordnung zur Sicherung guter wissenschaftlicher Praxis und zum Umgang mit wissenschaftlichem Fehlverhalten (Amtliche Mitteilung der Universität zu Köln AM 132/2020) der Universität zu Köln gelesen habe und verpflichte mich hiermit, die dort genannten Vorgaben bei allen wissenschaftlichen Tätigkeiten zu beachten und umzusetzen.

Köln, den 27.08.2023

Unterschrift: *L. Goesmann*

Danksagung

Mit inniger Dankbarkeit widme ich diese Arbeit meinen Eltern, meiner Schwester und meinen Großeltern, die mich in jeder Phase meines Lebens begleitet und unterstützt haben.

Ein besonderes Maß an Dankbarkeit möchte ich meinem Promotionsbetreuer, Herrn Univ.-Prof. Dr. Dr. Ludwig M. Heindl, entgegenbringen. Gleichzeitig möchte ich insbesondere auch Frau Dr. N. Refaian meinen aufrichtigen Dank aussprechen. Ihre wertvollen Einblicke und tatkräftige Unterstützung haben einen bedeutenden Beitrag zur Entwicklung dieser Arbeit geleistet.

Darüber hinaus danke ich dem Zentrum für Augenheilkunde der Medizinischen Fakultät der Universität zu Köln und insbesondere der Arbeitsgruppe Ophthalmo-Onkologie für die großartige Zusammenarbeit.

Meiner Familie

Inhaltsverzeichnis

Abkürzungsverzeichnis	7
1. Zusammenfassung	8
2. Einleitung	9
2.1. <i>Das uveale Melanom</i>	<i>9</i>
2.2. <i>Das Tumor Microenvironment</i>	<i>10</i>
2.3. <i>Immuncheckpoints und Checkpoint-Inhibitoren</i>	<i>10</i>
2.3.1. <i>Lymphocyte activation gene-3</i>	<i>11</i>
2.3.2. <i>Galectin-3</i>	<i>11</i>
2.3.3. <i>LSEctin.....</i>	<i>11</i>
2.4. <i>Ziel der Arbeit.....</i>	<i>12</i>
3. Publikation	12
4. Diskussion	13
4.1. <i>Tumorcharakteristika.....</i>	<i>13</i>
4.2. <i>Makrophagen</i>	<i>14</i>
4.3. <i>Blutendothelzellen</i>	<i>15</i>
4.4. <i>Lymphendothelzellen</i>	<i>16</i>
4.5. <i>Immuncheckpoints und Checkpoint-Inhibitoren</i>	<i>16</i>
4.6. <i>Limitationen der Forschungsarbeit und Ausblick</i>	<i>17</i>
5. Literaturverzeichnis	18

Abkürzungsverzeichnis

BEC	blood endothelial cells
CTLA-4	cytotoxic T-lymphocyte antigen 4
IHC	Immunohistochemistry
LAG-3	lymphocyte activation gene-3
LEC	lymph endothelial cells
mm	Millimeter
PD-1	programmed cell death protein 1
PD-L1	programmed cell death-ligand 1
TME	Tumor Microenvironment
UM	uveales Melanom
µm	Mikrometer

1. Zusammenfassung

Die vorliegende Arbeit ist die erste Studie zum Tumor Microenvironment des uvealen Melanoms, welche die Lokalisation innerhalb des Tumors und innerhalb des Auges berücksichtigt und analysiert. Das uveale Melanom ist der häufigste bösartige Tumor am Auge des Erwachsenen. Unabhängig von der Behandlung des Primärtumors verstirbt langfristig die Hälfte der Patienten aufgrund von Metastasen.

Das Tumor Microenvironment besteht aus allen zellulären und nicht-zellulären Bestandteilen eines soliden Tumors, mit Ausnahme der Tumorzellen selbst. Die vorliegende Studie vermittelt ein detaillierteres Verständnis über das Tumor Microenvironment des uvealen Melanoms. Ziel ist es, Grundlagen für neue therapeutische Angriffspunkte auszuarbeiten.

Die Lokalisationen verschiedener Zelltypen des Tumor Microenvironments wurden mittels Fluoreszenzimmunhistochemie analysiert. Darüber hinaus wurde das Vorkommen der Immuncheckpoints LAG-3, Galectin-3 und LSECtin untersucht, um die potenzielle Wirksamkeit von Therapien mit Immuncheckpoint-Inhibitoren zu untersuchen.

Eine zentrale Erkenntnis ist, dass Blutgefäße vornehmlich im mittleren Teil des Tumors lokalisiert sind, während Immunzellen überwiegend im peripheren Bereich des Tumors vorkommen. Darüber hinaus waren LAG-3 und Galectin-3 stark vertreten, während LSECtin kaum nachzuweisen war. Sowohl die vorherrschende Lage der tumorassoziierten Makrophagen im äußeren Bereich des Tumors, als auch das hohe Vorkommen von LAG-3 und Galectin-3 im uvealen Melanom könnten als vielversprechende neue Therapieansätze fungieren.

2. Einleitung

2.1. Das uveale Melanom

Das uveale Melanom ist der häufigste und zugleich auch bösartigste Tumor des Auges beim Erwachsenen. Uveale Melanome entstehen aus intraokularen Melanozyten der Uvea, bestehend aus der Choroidea, dem Ziliarkörper und der Iris. Die Mehrheit der uvealen Melanome entsteht in der Choroidea (<90 %), während der Ziliarkörper und die Iris seltener betroffen sind (>10 %) ¹⁻³. Die Inzidenzrate des uvealen Melanoms liegt zwischen 2 und 8 Fällen pro eine Million Menschen pro Jahr bei Kaukasiern in Europa und den USA, wobei die meisten Patienten älter als 60 Jahre sind ^{2,4-6}.

Eine aktuelle Studie über die Inzidenz und Überlebensrate von Patienten mit uvealem Melanom in Deutschland, die 1828 Patienten zwischen 2013 und 2015 einbezog, zeigte eine altersstandardisierte Inzidenz von 5,1 Fällen pro eine Million Menschen pro Jahr, wobei das mediane Alter bei Diagnosestellung bei 67 Jahren lag ³.

Verschiedene Studien zur Prognose des uvealen Melanoms haben histopathologische und zytogene Risikofaktoren herausgearbeitet, wie beispielsweise uveale Melanome des epitheloiden Zelltyps, ein hoher Anteil tumorinfiltrierender Makrophagen und die Tumorgröße. Darüber hinaus wurden verschiedene andere Risikofaktoren ermittelt, wie helle Hautfarbe, helle Irisfarbe und eine hohe Anzahl von Hautnävi ^{1,7}. Uveale Melanome weisen spezifische somatische chromosomale Veränderungen und Genmutationen auf. Etwa 90 % weisen eine treibende Mutation in GNAQ oder GNA11 auf, welche den MAPK-Signalweg aktiviert. Andere gehäuft auftretende Mutationen sind BAP1 (39 – 51 %), EIF1AX (12 – 21 %) und SF3B1 (10 – 22 %) ⁷⁻¹³. Etwa 50 % der Patienten mit uvealem Melanom haben eine Monosomie 3. Diese ist mit dem Auftreten von Metastasen und durch Metastasen bedingten Todesfällen assoziiert, da bis zu 75 % der Patienten mit Monosomie 3 Metastasen entwickeln ¹⁴⁻¹⁷.

Die metastatische Ausbreitung des uvealen Melanoms erfolgt fast ausschließlich hämatogen, wobei die Leber mit etwa 90 % die häufigste Lokalisation ist. Metastasen finden sich ansonsten zu etwa 30 % in der Lunge und zu etwa 15 % in den Knochen ^{18,19}. Eine lymphatische Ausbreitung ist selten und tritt hauptsächlich bei sekundärer extraokulärer Tumorausdehnung auf, welche in etwa 10 % der Fälle auftritt ²⁰⁻²³.

Die aktuellen therapeutischen Optionen für primäre uveale Melanome umfassen bulbuserhaltende Therapien, wie Strahlentherapie (Brachy- oder Teletherapie), transpupillare Thermotherapie und chirurgische Resektion, sowie als Ultima Ratio die Enukleation des Auges. Unabhängig von der Behandlung des Primärtumors ist die Prognose schlecht. Etwa die Hälfte der Patienten mit uvealem Melanom verstirbt langfristig an den Folgen der Metastasierung ²⁴⁻²⁶.

Die 10-Jahres-Rate für Metastasen beim Ziliarkörpermelanom wird auf 33 % geschätzt, während sie beim choroidalen Melanom bei 25 % und beim Irismelanom bei 7 % liegt¹⁷. Im Falle der Ausbreitung von Metastasen sind derzeit keine der aktuellen Therapien hinreichend wirksam⁷.

2.2. Das Tumor Microenvironment

Das Tumor Microenvironment umfasst alle zellulären und nichtzellulären Bestandteile eines soliden Tumors, mit Ausnahme der eigentlichen Tumorzellen. Es handelt sich um eine heterogene, komplexe und vielseitige Struktur. Darunter fallen unter anderem Immunzellen, Endothelzellen, Fibroblasten, extrazelluläre Matrix und Signalmoleküle, die vom Tumor und den umgebenden Zellen produziert werden. Es findet eine ständige Modifikation des Tumor Microenvironments statt, da alle Komponenten interagieren und somit den Verlauf und die Ausbreitung des Tumors beeinflussen, während der Tumor selbst ebenfalls das Tumor Microenvironment beeinflusst^{27,28}. Zum Beispiel fördert eine Entzündung, welche durch einwandernde Immunzellen verursacht wird, die Angiogenese, welche wiederum die metastatische Ausbreitung des Tumors fördert²⁹.

Die Heterogenität des Tumor Microenvironments, also die Variation in der Zusammensetzung und Funktion ihrer verschiedenen Bestandteile, wurde bereits an verschiedenen nicht-okularen Tumorentitäten untersucht, einschließlich Brustkrebs, Lungenkrebs und Hautmelanom³⁰⁻³². Ein detailliertes Verständnis über die Zusammensetzung und Interaktion des Tumor Microenvironments des uvealen Melanoms zu erlangen ist von entscheidender Bedeutung für die Entwicklung neuer effektiver therapeutischer Optionen.

2.3. Immuncheckpoints und Checkpoint-Inhibitoren

Immuncheckpoints sind Regulierungspunkte des Immunsystems, die dazu dienen, die Intensität einer Immunreaktion zu kontrollieren und Autoimmunität zu verhindern. Sie bestehen in Form von Oberflächenrezeptoren, welche das Immunsystem bei Kontakt mit Liganden sowohl anregen als auch hemmen können. Mehrere Studien konnten zeigen, dass Tumorzellen die Immunantwort modulieren und sich antitumoröser Aktivität entziehen können, indem sie Immuncheckpoint-Signalwege aktivieren, welche immunsuppressive Funktionen induzieren^{33,34}. Immuncheckpoint-Inhibitoren sind eine Klasse von Medikamenten, die entwickelt wurden, um diese Mechanismen zu blockieren, um so die antitumoröse Immunantwort zu fördern.

Die Entwicklung von Therapien auf Basis von Immuncheckpoint-Inhibitoren ist ein vielversprechender Durchbruch in der Krebsbehandlung, beispielsweise beim Mamma-Karzinom und beim malignen Melanom der Haut. Einige Immuncheckpoint-Inhibitoren wurden bereits für bestimmte Krebsarten zugelassen, während andere derzeit klinische Studien durchlaufen. Bis heute hat sich das uveale Melanom gegenüber der Checkpoint-Immuntherapie als sehr un-

empfindlich erwiesen³⁵⁻³⁷. Folglich bedarf es eines genaueren Wissens über Immuncheckpoints beim uvealen Melanom, um es für Therapien mit Immuncheckpoint-Inhibitoren zugänglich zu machen.

2.3.1. Lymphocyte activation gene-3

Das Lymphocyte activation gene-3 ist ein Typ-I-Transmembranprotein, das auf der Oberfläche von Effektor-T-Zellen und regulatorischen T-Zellen exprimiert wird. LAG-3 dient als hemmender Korezeptor, der mit CD4-, CD8- und CD3-Molekülen kolokalisiert, um übermäßige Immunreaktionen zu verhindern^{38,39}. In den letzten Jahren haben verschiedene Studien gezeigt, dass die Hemmung von LAG-3 es T-Zellen ermöglicht, ihre zytotoxische Funktion wiederzugewinnen. Dadurch kann die unterdrückte Immunreaktion zurückgewonnen werden, was zu einer wiedererlangten antitumorösen Wirkung führt^{40,41}. Darüber hinaus wurde LAG-3 als Indikator für die Tumorprognose identifiziert. Beim nicht-kleinzelligen Lungenkrebs beispielsweise, deutet ein hoher LAG-3-Spiegel auf eine schlechte Prognose hin, während er beim Magenkarzinom und Melanom mit einer besseren Prognose assoziiert ist⁴². Beim uvealen Melanom konnte ein hoher LAG-3-Spiegel mit Hochrisiko-Tumorparametern in Verbindung gebracht werden⁴³.

2.3.2. Galectin-3

Galectin-3 ist ein Ligand von LAG-3, der die T-Zell-Antwort über mehrere Mechanismen moduliert. In-vitro-Experimente haben gezeigt, dass Galectin-3 an LAG-3 binden muss, um eine durch Galectin-3 vermittelte Unterdrückung von CD8-positiven T-Zellen zu bewirken. Folglich müsste die Hemmung von Galectin-3 durch einen Immuncheckpoint-Inhibitor zu einer gesteigerten Aktivität der T-Zellen und demnach zu einer stärkeren tumorspezifischen Immunantwort führen^{39,44}.

2.3.3. LSEctin

LSEctin ist ein Typ-II-Transmembranprotein, das in verschiedenen menschlichen Tumoren nachgewiesen wurde und ebenfalls ein Ligand von LAG-3 ist. Eine erhöhte Expression von LSEctin wurde in Blasenkarzinomen, gastroösophagealen Tumoren und Melanomen gefunden. Die Wechselwirkung zwischen LSEctin und LAG-3 hemmt die IFN- γ -Sekretion von T-Zellen, was zu einer reduzierten antitumorösen Immunantwort führt⁴⁵. Auf Basis dessen kann davon ausgegangen werden, dass die Hemmung des LSEctin/LAG-3-Komplexes durch Immuncheckpoint-Inhibitoren zu einer erhöhten antitumorösen Reaktion beiträgt, indem die IFN- γ -Sekretion von Effektor-T-Zellen wiederhergestellt wird.

2.4. Ziel der Arbeit

Viele Fragen hinsichtlich der Zusammensetzung, der Funktion und der Wirkmechanismen des Tumor Microenvironment des uvealen Melanoms sind bisher noch wenig erforscht und daher offen.


Die vorliegende Arbeit ist die erste Untersuchung der Zusammensetzung des Tumor Microenvironment des uvealen Melanoms mit Bezug auf die Lokalisierung innerhalb des Tumors, sowie innerhalb des Auges.

Ziel dieser Arbeit ist es, mithilfe des speziell für das uveale Melanom entwickelten Studiendesigns, detailliertere Kenntnisse über das Tumorenvironment zu erlangen. Dies soll dazu dienen, Besonderheiten herauszuarbeiten, um so Grundlagen für neue therapeutische Strategien zu finden und im besten Fall die Prognose von Patienten mit uvealem Melanom zu verbessern.

3. Publikation

Article

Characterization and Quantitation of the Tumor Microenvironment of Uveal Melanoma

Lara Goesmann ¹, Nasrin Refaian ^{1,*}, Jacobus J. Bosch ^{1,2,3,4}  and Ludwig M. Heindl ^{1,2}

¹ Department of Ophthalmology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany; lgoesman@smail.uni-koeln.de (L.G.); jbosch@chdr.nl (J.J.B.); ludwig.heindl@uk-koeln.de (L.M.H.)

² Center for Integrated Oncology (CIO) Aachen Bonn Cologne Duesseldorf, 50937 Cologne, Germany

³ Centre for Human Drug Research, 2333 CL Leiden, The Netherlands

⁴ Leiden University Medical Center, 2333 ZA Leiden, The Netherlands

* Correspondence: nasrin.refaian@uk-koeln.de

Simple Summary: This is the first study on the tumor microenvironment of uveal melanoma with special regard to the localization within the tumor and the eye. Uveal melanoma is the most common malignant tumor of the eye in adults. Regardless of the treatment of the primary tumor, half of the patients with uveal melanoma die due to metastasis in the long run. The major findings of this study are that blood vessels are mainly located in the middle of the tumor and that immune cells (especially CD68-immunopositive macrophages) are mostly found in the outer section of the tumor. Furthermore, this study found a high representation of lymphocyte activation gene-3 (LAG-3) and Galectin-3 in uveal melanoma. These findings could set a foundation for new therapeutic strategies aimed at improving the survival rate of patients with uveal melanoma.

Abstract: Uveal melanoma (UM) is a highly malignant tumor of the eye. Metastatic spread of UM occurs almost exclusively via blood vessels and is of tremendous interest, as half of the patients with uveal melanoma die of metastasis in the long run. The tumor microenvironment consists of all cellular and non-cellular compounds of a solid tumor, except for the tumor cells. This study aims to provide a more detailed understanding of the tumor microenvironment of UM to build the foundation for new therapeutic targets. Fluorescence immunohistochemistry was performed to examine the localization of various cell types in the tumor microenvironment in UM. Furthermore, the presence of LAG-3 and its ligands Galectine-3 and LSECtin was examined to evaluate the potential efficacy of immune checkpoint inhibitor-based therapies. The main findings are that blood vessels are mainly located in the middle of the tumor, and that immune cells are mostly found in the outer section of the tumor. LAG-3 and Galectine-3 were found to be highly represented, whereas LSECtin barely occurred in UM. Both the predominant location of tumor-associated macrophages in the outer section of the tumor and the high presence of LAG-3 and Galectine-3 in the UM serve as attainable therapeutic targets.

Keywords: ocular melanoma; uveal melanoma; choroidal melanoma; tumor microenvironment; fluorescence immunohistochemistry; tumor-associated macrophages; immune checkpoint inhibitors



Citation: Goesmann, L.; Refaian, N.; Bosch, J.J.; Heindl, L.M. Characterization and Quantitation of the Tumor Microenvironment of Uveal Melanoma. *Biology* **2023**, *12*, 738. <https://doi.org/10.3390/biology12050738>

Academic Editor: Giorgio Mangino

Received: 18 March 2023

Revised: 6 May 2023

Accepted: 14 May 2023

Published: 19 May 2023



Copyright: © 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Uveal melanoma (UM) is the most common and malignant tumor of the eye in adults. UMs arise from intraocular melanocytes in the uveal tract of the eye, which consists of the choroid, the ciliary body, and the iris. The majority of UMs are formed in the choroid (<90%), while the ciliary body and the iris are less commonly affected (>10%) [1–3]. The incidence rate of UM is between 2 and 8 cases per million people per year in Caucasians in Europe and the US, with most patients being older than 60 years [2,4–6]. In a recent study of the incidence and survival of UM in Germany, involving 1828 patients between 2013 and

2015, the age-standardized incidence was 5.1 per million people per year, with a median age of 67 years at diagnosis [3].

Various studies on the prognosis of UM have elaborated histopathological and cytogenic risk factors, such as UM of the epithelioid cell type, increased tumor-infiltrating macrophages, and tumor size. In addition, several other risk factors were elaborated, such as fair skin color, light iris color, and numerous skin naevi [1,7]. UMs harbor specific somatic chromosomal alterations and gene mutations. Approximately 90% of UMs have a driver mutation in either *GNAQ* or *GNA11*, which activates the MAPK signaling pathway. Other commonly occurring mutations found in UM are *BAP1* (39–51%), *EIF1AX* (12–21%), and *SF3B1* (10–22%) [7–13]. About 50% of UMs have monosomy 3, which is associated with the occurrence of metastasis and metastasis-related death, as up to 75% of patients with monosomy 3 develop metastases [14–17].

Metastatic spread of UMs occurs almost exclusively via blood vessels, with the liver being the most frequent metastatic site at about 90%. Other typical metastatic targets are the lungs at about 30% and the bones at about 15% [18,19]. Lymphatic metastasis is rare and occurs predominantly in cases of secondary extraocular tumor extension, which occurs in about 10% of UMs [20–23].

Current therapeutic options for primary UMs include bulbus-preserving therapies such as radiotherapy (brachy- or teletherapy), transpupillary thermotherapy, and surgical resection, as well as enucleation of the eye. Regardless of the treatment of the primary tumor, the prognosis is poor as half of the patients with UM die of metastasis in the long run [24–26]. The 10-year rates of metastasis of ciliary body melanoma were found to be 33%, whilst for choroidal melanoma it was 25% and 7% for iris melanoma [17]. However, none of the therapeutic options are effective when metastatic spread has taken place. This is largely owing to the lack of knowledge about how tumor cells interact with their respective tumor microenvironments [7].

The tumor microenvironment (TME) includes all cellular and noncellular compounds of a solid tumor, except for the tumor cells. It is a heterogeneous, complex, and versatile environment. There is constant modification of the TME as all components interact and influence the progression and spread of the tumor, whilst the tumor itself influences the TME simultaneously [27,28]. For example, inflammation caused by immigrating immune cells promotes angiogenesis, which eventually supports metastatic spread [29]. The heterogeneity of the TME has already been examined in various nonocular tumor entities, including breast cancer, lung cancer, and skin melanoma [30–32]. However, a more detailed understanding is required of how the TME of UM composes as well as how it interacts.

The development of immune checkpoint inhibitor-based therapies has been a promising breakthrough in cancer treatment, for example, in breast cancer and malignant melanoma of the skin. Some immune checkpoint inhibitors have already been approved for certain cancer types, whilst others are currently undergoing clinical trials. Many studies have proven that tumor cells can modulate the immune response to escape antitumor activity by activating immune checkpoint pathways that induce immunosuppressive functions [33,34]. To date, UMs have been very unresponsive to checkpoint immunotherapy [35–37]. Thus, a deeper knowledge of checkpoints in UMs is needed to make UMs amenable to immune checkpoint inhibitor-based therapies.

Lymphocyte activation gene-3 (LAG-3) is a type I transmembrane protein expressed on the surface of effector T-cells and regulatory T-cells. LAG-3 serves as an inhibitory coreceptor that co-localizes with CD4, CD8, and CD3 molecules to prevent excessive immune responses [38,39]. In recent years, various studies have shown that the inhibition of LAG-3 allows T-cells to regain their cytotoxic function and that the suppressed immune response can be reduced, resulting in a regained antitumor effect [40,41]. Furthermore, LAG-3 has been identified as an indicator of tumor prognosis. In non-small-cell lung cancer, for instance, a high level of LAG-3 indicates a poor prognosis, whereas in gastric carcinoma and melanoma, it is associated with a better prognosis [42]. In UM, a high level of LAG-3 was found to be associated with high-risk tumor parameters [43].

Galectin-3 is a ligand of LAG-3 that modulates the T-cell response via several mechanisms. *In vitro* experiments have shown that Galectin-3 needs to bind LAG-3 for Galectin-3-mediated suppression of CD8-positive T-cells. Therefore, inhibition of Galectin-3 through an immune checkpoint inhibitor should result in T-cell activation and a stronger tumor-specific immune response [39,44].

LSECTin is a type II transmembrane protein that has been detected in various human tumors and is a ligand of LAG-3 as well. Increased expression of LSECTin has been found in bladder, gastroesophageal, and melanoma tumors. The LSECTin/LAG-3 interaction inhibits IFN- γ secretion from T-cells, resulting in a reduced antitumor immune response [45]. Thus, inhibition of the LSECTin/LAG-3 complex through immune checkpoint inhibitors could help increase the antitumor response by restoring the IFN- γ secretion from effector T-cells.

2. Materials and Methods

2.1. Tissue Sample Selection and Processing

The study cohort included 18 patients with choroidal UM who underwent enucleation in the Department of Ophthalmology at the University of Cologne, Germany between 2007 and 2017. With approval for scientific examination from the local Ethics Committee of the University of Cologne (Medizinische Fakultät der Universität zu Köln—Geschäftsstelle der Ethikkommission; 15–362; 26 July 2016), the collection was obtained from the laboratory for histology and ophthalmopathology. An expert pathologist reviewed all cases and confirmed the diagnosis. All tumor characteristics were obtained from the pathology reports.

The enucleated eyes were formalin-fixed and paraffin-embedded. Afterwards, multiple four μ m-thick serial sections were cut from the tissue blocks for subsequent analyses.

2.2. Fluorescence Immunohistochemistry (IHC)

In all cases, we performed IHC using a double-staining technique under optimized conditions, including specified antigen retrieval, autofluorescence quenching, concentrations, incubation times, and incubation temperatures. Melanoma Pan, a ready to use antibody mix consisting of anti-HMB45-, anti-Mart-1/Melan A-, and anti-Tyrosinase-antibody was applied on all slides to prove melanoma cells and define the exact tumor area. Additionally, a second primary antibody was applied to prove the presence of another specific cell type represented in the TME.

Staining protocol: Firstly, deparaffinization was performed using xylene. The slides were rehydrated using 100%, 70%, and 50% ethanol and washed with distilled water afterwards. Antigen retrieval was performed with either Fast Enzyme (CD68 and Pan-CK) or with Retrieval Solution (CD31, CD3, LYVE1) for 30 min at 96 °C. For autofluorescence quenching, True Black (1:20 in 70% ethanol) was applied to all slides for 15 seconds. 5–10% normal serum (host species of the secondary antibody) diluted in PBS was applied to all slides for 10 min. The primary antibodies were diluted in antibody dilution buffer, and the mixture was applied to the slides according to the concentrations, incubation times, and temperatures listed in Table 1. The secondary antibodies (Invitrogen, goat anti-mouse IgG Alexa Fluor 488 and Invitrogen, goat anti-rabbit IgG Alexa Fluor 546) were diluted in PBS (1:250) and the samples were incubated for 60 min in the dark. Nucleus staining was performed with DAPI diluted in PBS (1:2000), and the mixture was applied to the slides for 2 min. Fluorescence Mounting Medium was applied, and the slides were covered with coverslips and stored at approximately 4 °C in the dark.

Every incubation step was performed at room temperature unless stated otherwise. After every incubation step, the slides were washed three times with PBS for 5 min each.

Table 1. List of primary antibodies, including concentrations, incubation times, temperatures, and identification numbers.

Primary Antibody	Concentration	Incubation Time	Temperature	Manufacturer Identification
Melanoma Pan	ready to use	30 min	RT	#DCS, MI875R06
CD31	1:50	30 min	RT	#abcam, ab76533
Pan Cytokeratin (Pan-CK)	1:100	30 min	RT	#origene, DP010
CD68	1:100	45 min	RT	#abcam, ab213363
CD3	1:75	45 min	RT	#DCS, CI597C002
LYVE1	1:25	over night	4 °C	#abcam, ab36993
LAG-3	1:100	60 min	RT	#novusbio, NBP1-97657
LSECTin	1:100	60 min	RT	#ThermoFisher, PA5-53116
Galectin-3	1:200	60 min	RT	#ThermoFisher, 14-5301-82

2.3. Image Acquisition and Analysis

The stained slides were imaged using a Zeiss confocal microscope and Zeiss Zen Blue software at 25× magnification. The areas of image acquisition were determined beforehand based on the localization within the tumor (outer section, intermediary section, and inner section) and on the localization within the eye (sclera side, middle part, and vitreous body side) (Figure 1). Accordingly, a total of 14 images per slide were taken.




Figure 1. Template for image acquisition. (A) Based on the localization within the tumor. Inner section (images 1a–d), intermediary section (images 2–5), outer section (images 6–11) (B) Based on the localization within the eye. Middle part (images 1a–d), sclera side (images 8–10), vitreous body side (images 6, 7, 11). (C) Overview of a histological specimen.

Image segmentation was carried out using the machine-learning segmentation tool Ilastik with the respective workflow being Pixel Classification. By applying this workflow, we assigned labels to pixels and trained the classifier to separate the object classes. This ensured objective and reproducible results. The area covered by immunopositive cells was determined and analyzed.

2.4. Statistical Analysis

All statistical analyses were performed using the GraphPad Prism in consultation with a medical statistician at the University of Cologne. For each tumor, the results were categorized as paired or nonparametric. Thus, the Wilcoxon test or Friedman test was performed throughout.

3. Results

The tumor characteristics at enucleation are listed in Table 2. The patients' median age was 69 and gender was equally distributed. The cohort consisted of enucleated eyes with choroidal UM, which had a mean basal diameter of 17.21 mm and a mean height of 7.37 mm. Immunohistochemistry was performed after enucleation. The spindle cell type was found in 47% of cases, the epithelioid cell type was found in 13% of cases, and the mixed cell type was found in 40% of cases. A semiquantitative classification of the melanization of the tumor from + to ++++ showed that 44.44% of the tumors were strongly pigmented (+++ and ++++), whereas 55.55% of the tumors were less pigmented (+ and ++).

Table 2. Tumor characteristics at enucleation of the eye. Semiquantitative classification of the tumor melanization from + (less pigmented) to ++++ (strongly pigmented).

Nr.	Age at Enucleation (n = 18)	Gender (n = 18)	Basal dia-Meter of Tumor (n = 14)	Hight of Tumor (n = 14)	Type of Tumor (n = 15)	Semiquantitative Classification of Melanization
1	44	f	15 mm	6.5 mm	spindle cell type	+++
2	80	m	22 mm	6.5 mm	spindle cell type	+++
3	69	f	15 mm	10 mm	epithelioid cell type	+
4	69	m	12 mm	4.3 mm	spindle cell type	+
5	79	f	26 mm	7.5 mm	epithelioid cell type	++
6	47	m	18 mm	7.5 mm	spindle cell type	+
7	65	f				+++
8	74	m	20 mm	12 mm	mixed cell type	+
9	83	m	13 mm	5 mm	spindle cell type	++
10	76	f	21 mm	5 mm	mixed cell type	++
11	62	f	15 mm	6 mm	mixed cell type	++
12	22	f	14 mm	11 mm	spindle cell type	+
13	89	m	13 mm	10.5 mm	mixed cell type	+++
14	47	m			spindle cell type	++
15	47	m	16 mm	6 mm		+++
16	86	f			mixed cell type	+++
17	47	f				+++
18	83	m	21 mm	5.4 mm	mixed cell type	++++

Figure 2 shows the double fluorescence immunohistochemistry results for the specific markers. The distribution of the various cell types and their percentage of covered area within the tumor are depicted in Figure 3. We found major differences in the distribution of the cell types, with melanoma cells and immune cells being the predominant ones. Among the immune cells, macrophages were more abundant than T-lymphocytes. Within the tumor, an average of 4.93% was covered by CD68-immunopositive macrophages and 1.33% by CD3-immunopositive T-lymphocytes. The differences between these cell types were found to be nonsignificant ($p = 0.750$).




Figure 2. Double fluorescence IHC staining in choroidal melanoma. Melanoma Pan (green) was applied on all slides to define the exact tumor area. Various other cell types were identified using different markers (red). (A) 1: CD68-immunopositive macrophages. (B) 1: CD3-immunopositive T-lymphocytes. (C) 1: CD31-immunopositive blood endothelial cells. (D) 1: LYVE1-immunopositive lymph endothelial cells. (E) 1: PanCK-immunopositive epithelial cells. (A–E) 2: Melanoma Pan-immunopositive melanoma cells. (A–E) 3: Dapi. (A–E) 4: Merged image. (×25, scale bar = 100 μm).




Figure 3. Overall outcome of the percentage area covered by different cell types in choroidal melanoma, arranged in the order from most to least covered area. Melanoma Pan-immunopositive melanoma cells and CD68- and CD3-immunopositive immune cells were represented the most, followed by CD31-immunopositive blood endothelial cells (BEC). LYVE1-immunopositive lymph endothelial cells (LEC) and PanCK-immunopositive epithelial cells were the least represented cell types. Significance levels: ns = $p > 0.05$, * = $p \leq 0.05$, ** = $p \leq 0.01$, and **** = $p \leq 0.0001$.

CD31-immunopositive blood endothelial cells covered a mean area of 0.39% and were significantly less present than CD68-immunopositive macrophages ($p = 0.008$). However, LYVE1-immunopositive lymph endothelial cells and CD31-immunopositive epithelial cells were significantly less abundant than immune cells, they covered a mean area of 0.06% each (LYVE1 vs. CD68, $p < 0.001$; LYVE1 vs. CD3, $p = 0.002$; CD31 vs. CD68, $p = 0.008$; CD31 vs. CD3, $p > 0.9999$).

In order to clarify whether the distribution of the cell types is influenced by their localization within the tumor, we categorized the tumor into outer, intermediary, and inner sections. The results are illustrated in Figure 4.

Most of the cell types showed significant difference between the outer section and the inner sections; immune cells and lymph endothelial cells were mostly located in the outer section, whereas blood endothelial cells were predominantly present in the inner section. Compared to the inner section of the tumor, a significantly larger area was allocated to CD68-immunopositive macrophages ($p = 0.003$) and CD3-immunopositive T-lymphocytes ($p = 0.014$) in the outer section. Additionally, a significantly larger area was covered by LYVE1-immunopositive cells in the outer section compared to the inner section ($p = 0.003$). Furthermore, none of the cell types showed significant differences between the inner section and the intermediary section. Epithelial cells showed no significant differences in distribution.

Apart from the localization within the tumor, we also paid attention to the distribution of the cell types based on the localization within the eye. We did this by subdividing the tumor into a sclera side, a middle part, and a vitreous body side (Figure 5).




Figure 4. Distribution of the percentage area covered by different cell types based on the localization within the tumor. (A) Significantly more Melanoma Pan-immunopositive melanoma cells in the outer section compared to the intermediary section. (B) Significantly more CD68-immunopositive macrophages in the outer section compared to the inner section. (C) Significantly more CD3-immunopositive T-lymphocytes in the outer section compared to the inner section. (D) Significantly more CD31-immunopositive blood endothelial cells in the inner section and in the intermediary section compared to the outer section. (E) Significantly more LYVE1-immunopositive lymph endothelial cells in the outer section compared to the inner section. (F) No significant differences in the distribution of PanCK-immunopositive epithelial cells. Significance levels: ns = $p > 0.05$, * = $p \leq 0.05$, ** = $p \leq 0.01$, *** = $p \leq 0.001$ and **** = $p \leq 0.0001$.

The immune cell types showed a similar distribution pattern. Compared to the middle of the tumor, more immune cells were localized in the vitreous body side and the sclera side. However, significantly more CD68-immunopositive macrophages were detected in the sclera side compared to the middle section ($p = 0.037$), whereas significantly more CD3-immunopositive T-lymphocytes were detected in the vitreous side compared to the middle section ($p = 0.005$). Interestingly, CD31-immunopositive blood endothelial cells covered significantly more area in the middle section compared to the sclera ($p = 0.005$) and vitreous body side ($p = 0.003$). LYVE1-immunopositive lymph endothelial cells were mostly located in the vitreous body side, with a significant difference compared to the middle section ($p = 0.008$). None of the cell types presented a significant difference in distribution between the sclera side and the vitreous body side of the tumor. In addition, no significant difference in distribution was found for epithelial cells.

Figure 6 shows the fluorescence immunohistochemistry of LAG-3, LSECTin, and Galectin-3. The overall results for the area covered by the stated markers are depicted in Figure 7. Galectin-3 occurred the most, with an average of 2.48% of the area being covered, followed by LAG-3 with 0.87% of the covered area. The difference between these cell types was found to be nonsignificant ($p > 0.9999$). Almost no area was covered by LSECTin (0.002%), and the differences between LSECTin and the other two markers were found to be significant (LAG-3 $p = 0.0003$, Galectin-3 $p < 0.0001$).




Figure 5. Distribution of the percentage area covered by different cell types based on the localization within the eye. (A) No significant difference in the distribution of Melanoma Pan-immunopositive melanoma cells. (B) Significantly more CD68-immunopositive macrophages in the sclera side compared to the middle section. (C) Significantly more CD3-immunopositive T-lymphocytes in the vitreous body side compared to the middle section. (D) Significantly more CD31-immunopositive blood endothelial cells in the sclera side and in the vitreous body side compared to the middle section. (E) Significantly more LYVE1-immunopositive lymph endothelial cells in the vitreous body side compared to the middle section. (F) No significant differences in the distribution of PanCK-immunopositive epithelial cells. Significance levels: ns = $p > 0.05$, * = $p \leq 0.05$, and ** = $p \leq 0.01$.




Figure 6. Fluorescence IHC staining in choroidal melanoma. (A) Lymphocyte activation gene-3. (LAG-3) (1: LAG-3 (green), 2: DAPI (blue), 3: LAG-3 (green) and DAPI (blue)). (B) Galectin-3 (1: Galectin-3 (red), 2: DAPI (blue), 3: Galectin-3 (red) and DAPI (blue)). (C) LSEctin (1: LSEctin (red), 2: DAPI (blue), 3: LSEctin (red) and DAPI (blue)) (A–C) 4: negative control. ($\times 25$, scale bar = 100 μm).




Figure 7. Overall outcome of the percentage area covered by LAG-3, LSECTin, and Galectin-3 in choroidal melanoma. Galectin-3-positive cells were represented the most, followed by LAG-3-positive cells. LSECTin-positive cells were the least abundant. Significance levels: ns = $p > 0.05$, *** = $p \leq 0.001$ and **** = $p \leq 0.0001$.

Our previous examination has shown significant differences in the distribution of various cell types between the outer and inner sections. Accordingly, we subdivided the tumors into these sections to investigate the distribution of LAG-3, LSECTin, and Galectin-3. The results are summarized in Figure 8, showing no significant differences in the distribution of the previously mentioned. (LAG-3: outer section vs. inner section, $p = 0.3289$. LSECTin: outer section vs. inner section, $p = 0.6788$. Galectin-3: outer section vs. inner section, $p = 0.1297$).




Figure 8. Distribution of the percentage area covered by LAG-3, LSECTin and Galectin-3 based on the localization within the tumor. (A–C) No significant difference in the distribution of LAG-3, LSECTin and Galectin-3. Significance level: ns = $p > 0.05$.

Furthermore, the distribution of LAG-3, LSECTin, and Galectin-3 based on their localization within the eye has shown no significant differences. (LAG-3: sclera side vs. middle, $p > 0.9999$; middle vs. vitreous body side, $p = 0.6898$; sclera side vs. vitreous body side, $p > 0.9999$. LSECTin: sclera side vs. middle, $p > 0.9999$; middle vs. vitreous body side, $p = 0.9999$; sclera side vs. vitreous body side, $p > 0.9999$. Galectin-3: sclera side vs. middle, $p = 0.4719$; middle vs. vitreous body side, $p > 0.9999$; sclera side vs. vitreous body side, $p > 0.9999$). The results are depicted in Figure 9.




Figure 9. Distribution of the percentage area covered by LAG-3, LSECtin, and Galectin-3 based on the localization within the eye. (A–C) No significant differences in the distribution of LAG-3, LSECtin, and Galectin-3. Significance level: ns = $p > 0.05$.

4. Discussion

The present study is the first investigation of the composition of the TME of choroidal melanoma with respect to the localization within the tumor as well as within the eye. The aim is to set the foundation for new therapeutic strategies and targets in order to eventually improve the survival rate of patients with UMs.

We discovered the following new and important results: blood vessels are mainly located in the middle of the tumor, whereas LYVE1-immunopositive cells (lymph endothelial cells) and immune cells are mostly found in the outer section of the tumor. Within the outer section, CD68-immunopositive macrophages, CD3-immunopositive T-lymphocytes, and LYVE1-immunopositive cells occupied more area in the vitreous body side compared to the sclera side.

In our study cohort of 18 enucleated eyes, the median age of the patients at enucleation was 69 years. Recently, the majority of UMs were reported to occur at above 65 years of age in Germany, which coincides with our results [3]. Male and female patients were equally represented in our study group, supporting the results of a large study of 8033 eyes with UMs by Shields et al [46].

As the mean basal diameter of our study cohort was 17.21 mm, with a mean tumor height of 7.37 mm, all conclusions made from our results are solely applicable to large-sized tumors. The estimated 5-year mortality rates of patients with UM were found to be much higher (53%) for patients with large tumors (basal diameter > 15 mm and tumor thickness > 8 mm), than for patients with smaller tumors (16% for small tumors and 32% for medium-sized tumors) [1,47]. Furthermore, Shields et al. showed that each millimeter increase in tumor thickness was associated with an approximately 5% increase in the risk for metastasis after 10 years [46].

In our study cohort, the spindle cell type was found in 47% of cases, the epithelioid cell type in 13%, and the mixed cell type in 40% of cases. Tumor cell type is an important prognostic factor for UM. The Callender classification system subdivides UM into spindle A, spindle B, epithelioid, and mixed tumors [48]. Various studies have proven that UM of the spindle cell type has the best prognosis, whereas epithelioid cell melanoma has the worst prognosis [49–52]. We found that tumors of the epithelioid cell type were of a larger mean size (20.5 mm) than those of the spindle cell (15.66 mm) or mixed cell type (17.66 mm). We hypothesized that there is a positive correlation between the quantity of epithelioid cells and tumor growth, resulting in larger tumor sizes at enucleation of UM of the epithelioid or mixed cell type.

We found that the mean tumor area covered by CD68-immunopositive macrophages was 4.94%. Interestingly, the mean area in epithelioid cell tumors was 8.97%, in the mixed type it was 4.41%, and 3.04% in the spindle cell type. Makitie et al. found that a high quantity of tumor-infiltrating CD68-immunopositive macrophages is associated with the presence of epithelioid cells [53]. Our results support these findings, and we conclude

that the quantity of epithelioid cells in a tumor correlates strongly with the number of CD68-immunopositive macrophages, and therefore with tumor malignancy.

Macrophages have been investigated in various malignant cancer entities, such as ovarian tumors, pancreatic, rectal, and breast cancers [54–57]. Depending on the type of macrophages, they either provide defense against tumor cells (M1-type) or promote tumor cell proliferation (M2-type). Tumor-associated macrophages have been proven to mainly exhibit the M2 phenotype and are associated with the promotion of tumor cell proliferation, metastasis, and angiogenesis [58–62]. In this study, we found that CD68-immunopositive macrophages make up a large portion of the TME. Bronkehorst et al. have shown that most macrophages in UM are of the M2-type [61]. Based on these data and our finding that macrophages are the most abundant cell type after melanoma cells, the severe malignancy of UM may be due to the high presence of M2-macrophages. Hence, focusing on macrophages as therapeutic targets may play an important role in the treatment of UM in the future.

We also found that macrophages were mainly located in the outer section of the tumor. As M2-macrophages are proven to be related to tumor growth, it might be of interest to deplete or even erase these cells. Bisphosphonates (e.g., liposome-encapsulated clodronate) have shown great efficacy in macrophage depletion in *in vitro* and in *in vivo* mouse models [63–65]. For the purpose of macrophage depletion, high doses of systemic therapy would be necessary because the *in vivo* efficacy is limited by a short plasma half-life or by being excreted unaltered by the kidneys. However, such high doses cannot be applied in humans because of nephrotoxicity, osteonecrosis, and bone fractures [66,67]. Due to the predominant localization of macrophages in the outer section of choroidal melanoma, we conclude that it may be an efficient therapeutic option to undertake an intravitreal injection with a bisphosphonate of lower dose to achieve a sufficient local dose for macrophage depletion. This may stop tumor growth and lead to downsizing of the tumor, making it more responsive to thermo-, photodynamic-, or radiotherapy. In a study of 20 eyes of 20 pigmented rats, Nourinia et al. showed that up to 8 µg of intravitreal zoledronic acid seems to be safe in rat eyes [68]. The next steps for investigating this new therapeutic approach would be to examine the most suitable bisphosphonate, the necessary dose for macrophage depletion, and the maximum applicable *in vivo* dose in human eyes. We do not consider a bisphosphonate injection into the tumor itself, as this could cause cell seeding within the eye [69].

Another major finding of our study was the predominant localization of blood endothelial cells in the middle part of the tumor. Generally, in the early stages of tumor formation, hyperplastic growth takes place. Having reached a critical size, pre-existing blood vessels cannot provide sufficient oxygen and nutrients. Thereby, further tumor growth is impaired. However, tumor cells can overcome this stagnation by inducing tumor angiogenesis. The transition from initial hyperplasia to vascularized malignant tumor growth has been described and investigated as an “angiogenic switch” by several authors [70–72]. As a matter of fact, the formation of blood vessels plays a crucial role in the progression and differentiation of the TME. Having found that blood vessels in UMs are mainly located in the center of the tumor, we conclude that the formation and differentiation of the TME takes place radially, which ensures sufficient oxygen and nutrient supply in all parts of the tumor. Based on this, the tumor center must be the longest existing part of the tumor with the most time for angiogenesis, resulting in a high microvascular density. The major localization of blood vessels in the tumor center makes it difficult to treat choroidal melanoma from the outside. For choroidal melanomas of small sizes, this is carried out via transpupillary thermotherapy, photodynamic therapy, plaque radiotherapy, or proton beam radiotherapy. However, large tumor size limits the success of these therapies, and we conclude that this is due to the central localization of the blood vessels.

Besides epithelial cells, lymph endothelial cells occurred the least out of all cell types in our study. Furthermore, LYVE1-immunopositive cells were mostly found in the outer section of the tumor. LYVE1 is not only expressed in lymphatic endothelial cells but also in

macrophages and various structures in the anterior segment of the eye [23,73]. Moreover, Schroedl et al. showed in their study of 17 normal eyes that the adult human choroid does not contain typical lymphatic vessels but a significant amount of LYVE1-immunopositive macrophages [73]. Based on the small amount of LYVE1-immunopositive cells in our findings and the same predominant localization as determined for CD68-immunopositive macrophages, the functionality of these structures as lymphatic vessels remains vague. In the event that these structures were not lymphatic vessels, this would support various studies that could not detect intraocular lymphatic structures in UM [19,23,74].

The examination of LAG-3 and its ligands showed a high representation of Galectin-3 and LAG-3, whereas LSECtin was barely represented. Kashyap et al. that found high levels of LAG-3 were associated with UM with high-risk parameters and high metastatic potential. The large tumor sizes in our study group combined with the high representation of LAG-3 support this finding [75]. Furthermore, our results support the assumption made by Souri et al. that LAG-3 and Galectin-3 interact strongly in UM. Galectin-3 is known to bind LAG-3 on CD8-positive T-cells. Thus, the LAG-3/Galectin-3 interaction in UM may result in depleted activity of CD8-positive T-cells [43]. Durante et al. found LAG-3 to be the most dominant immune checkpoint in UM [76]. In our examination, the difference in the quantity of LAG-3 and Galectin-3 was found to be insignificant.

Immune checkpoint inhibitor-based therapies are a modern and promising approach for the treatment of various solid tumors, including metastatic cutaneous melanoma. In contrast, UM has shown a poor response to checkpoint immunotherapies such as cytotoxic T-lymphocyte antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) [33–35,37,77,78]. However, high expression of PD-1 and programmed cell death-ligand 1 (PD-L1) and the presence of tumor-infiltrating lymphocytes are associated with parameters for poor prognosis, such as loss of BAP-1, the epithelioid cell type, and liver metastasis [79]. Similarly, methylation of immune checkpoint genes, such as CTLA4, PD-1, PD-L1, and LAG-3, has been shown to correlate strongly with BAP1 mutation status and overall survival in UM. Therefore, DNA methylation tests for immune checkpoint genes should be used as predictive biomarkers for response to immunotherapy [80].

Considering the mean area covered by the various cell types, we analyzed an average of 13% of the total tumor area. Obviously, the TME consists of additional cell types and subtypes as well as noncellular compounds, which could not all be covered by the marker panel applied in this study. Moreover, one needs to be aware that the presented results arise from two-dimensional tumor slices, whereas the tumor itself is a complex three-dimensional construct. In summary, we have shown remarkable differences in the localization and the occurrence of various cell types in the TME of uveal melanoma. Based on these findings, a larger study group, an extended marker panel, and preclinical studies are required to support our results and explore new treatment approaches.

5. Conclusions

In the present study we have proven that the distribution of different cell types of the TME of UM shows remarkable differences in localization; blood vessels are mainly located in the middle of the tumor, whereas immune cells (especially CD68-immunopositive macrophages) are mostly found in the outer section of the tumor. LAG-3 and Galectin-3 have been equally represented in our findings, indicating that the inhibition of Galectin-3 through an immune checkpoint inhibitor may be a reasonable approach in UM treatment. These findings may pave the way for new therapeutic strategies aiming to improve the survival rate of patients with uveal melanoma.

Author Contributions: Conceptualization, N.R. and L.M.H.; methodology, L.G., N.R. and L.M.H.; validation, L.G. and N.R.; formal analysis, L.G.; investigation, L.G.; Ilastik-software, L.G.; data curation and statistical analysis, L.G. and N.R.; writing—original draft preparation, L.G. and N.R.; writing—review and editing, L.M.H. and J.J.B.; visualization, N.R.; supervision, N.R. and L.M.H.; project administration, N.R. and L.M.H.; funding acquisition, L.M.H. All authors have read and agreed to the published version of the manuscript.

Funding: Supported by the Koeln Fortune Program/Faculty of Medicine, University of Cologne to L.G, N.R, and L.M.H and the German Research Foundation (FOR2240, DFG-HE6743/3-2, DFG-HE6743/5-1, DFG-BO4000/2-1, and DFG-BO4000/3-1.

Institutional Review Board Statement: The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Ethics Committee of the University of Cologne (Medizinische Fakultät der Universität zu Köln - Geschäftsstelle der Ethikkommission; protocol code 15-362; 26.07.2016).

Informed Consent Statement: Informed consent was obtained from all subjects involved in the study.

Acknowledgments: The authors would like to thank Martina Becker, laboratory A. Wodarz, Peter Zentis, Christian Jüngst, and Konrad Koch for their support.

Conflicts of Interest: The authors declare no conflict of interest.

References

- Kaliki, S.; Shields, C.L. Uveal melanoma: Relatively rare but deadly cancer. *Eye* **2017**, *31*, 241–257. [[CrossRef](#)]
- McLaughlin, C.C.; Wu, X.C.; Jemal, A.; Martin, H.J.; Roche, L.M.; Chen, V.W. Incidence of noncutaneous melanomas in the U.S. *Cancer* **2005**, *103*, 1000–1007. [[CrossRef](#)] [[PubMed](#)]
- Mor, J.M.; Rokohl, A.C.; Dahm, S.; Kraywinkel, K.; Heindl, L.M. Epidemiology of uveal melanomas in Germany. *Acta Ophthalmol.* **2021**, *100*, e1774–e1775. [[CrossRef](#)]
- Aronow, M.E.; Topham, A.K.; Singh, A.D. Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1973–2013). *Ocul. Oncol. Pathol.* **2018**, *4*, 145–151. [[CrossRef](#)]
- Singh, A.D.; Turell, M.E.; Topham, A.K. Uveal melanoma: Trends in incidence, treatment, and survival. *Ophthalmology* **2011**, *118*, 1881–1885. [[CrossRef](#)]
- Virgili, G.; Gatta, G.; Ciccolallo, L.; Capocaccia, R.; Biggeri, A.; Crocetti, E.; Lutz, J.M.; Paci, E.; Group, E.W. Incidence of uveal melanoma in Europe. *Ophthalmology* **2007**, *114*, 2309–2315. [[CrossRef](#)] [[PubMed](#)]
- Jager, M.J.; Shields, C.L.; Cebulla, C.M.; Abdel-Rahman, M.H.; Grossniklaus, H.E.; Stern, M.H.; Carvajal, R.D.; Belfort, R.N.; Jia, R.; Shields, J.A.; et al. Uveal melanoma. *Nat. Rev. Dis. Primers* **2020**, *6*, 24. [[CrossRef](#)] [[PubMed](#)]
- Grisanti, S.; Ranjbar, M.; Tura, A.; Heindl, L.M.; Kakkassery, V. Uveal melanoma: Early detection as the key to successful personalized medicine. *Ophthalmologe* **2020**, *117*, 508–520. [[CrossRef](#)]
- Hoiom, V.; Edsgard, D.; Helgadottir, H.; Eriksson, H.; All-Ericsson, C.; Tuominen, R.; Ivanova, I.; Lundeberg, J.; Emanuelsson, O.; Hansson, J. Hereditary uveal melanoma: A report of a germline mutation in BAP1. *Genes Chromosomes Cancer* **2013**, *52*, 378–384. [[CrossRef](#)]
- Johansson, P.; Aoude, L.G.; Wadt, K.; Glasson, W.J.; Warriar, S.K.; Hewitt, A.W.; Kiilgaard, J.F.; Heegaard, S.; Isaacs, T.; Franchina, M.; et al. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. *Oncotarget* **2016**, *7*, 4624–4631. [[CrossRef](#)]
- Royer-Bertrand, B.; Torsello, M.; Rimoldi, D.; El Zaoui, I.; Cisarova, K.; Pescini-Gobert, R.; Raynaud, F.; Zografos, L.; Schalenbourg, A.; Speiser, D.; et al. Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing. *Am. J. Hum. Genet.* **2016**, *99*, 1190–1198. [[CrossRef](#)] [[PubMed](#)]
- Van Raamsdonk, C.D.; Bezrookove, V.; Green, G.; Bauer, J.; Gaugler, L.; O'Brien, J.M.; Simpson, E.M.; Barsh, G.S.; Bastian, B.C. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. *Nature* **2009**, *457*, 599–602. [[CrossRef](#)]
- Van Raamsdonk, C.D.; Griewank, K.G.; Crosby, M.B.; Garrido, M.C.; Vemula, S.; Wiesner, T.; Obenaus, A.C.; Wackernagel, W.; Green, G.; Bouvier, N.; et al. Mutations in GNA11 in uveal melanoma. *N. Engl. J. Med.* **2010**, *363*, 2191–2199. [[CrossRef](#)]
- Damato, B.; Dopierala, J.; Klaasen, A.; van Dijk, M.; Sibbring, J.; Coupland, S.E. Multiplex ligation-dependent probe amplification of uveal melanoma: Correlation with metastatic death. *Investig. Ophthalmol. Vis. Sci.* **2009**, *50*, 3048–3055. [[CrossRef](#)]
- Prescher, G.; Bornfeld, N.; Hirche, H.; Horsthemke, B.; Jockel, K.H.; Becher, R. Prognostic implications of monosomy 3 in uveal melanoma. *Lancet* **1996**, *347*, 1222–1225. [[CrossRef](#)]
- Scholes, A.G.; Damato, B.E.; Nunn, J.; Hiscott, P.; Grierson, I.; Field, J.K. Monosomy 3 in uveal melanoma: Correlation with clinical and histologic predictors of survival. *Investig. Ophthalmol. Vis. Sci.* **2003**, *44*, 1008–1011. [[CrossRef](#)] [[PubMed](#)]
- Shields, C.L.; Ganguly, A.; Bianciotto, C.G.; Turaka, K.; Tavallali, A.; Shields, J.A. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. *Ophthalmology* **2011**, *118*, 396–401. [[CrossRef](#)]
- Diener-West, M.; Reynolds, S.M.; Agugliaro, D.J.; Caldwell, R.; Cumming, K.; Earle, J.D.; Hawkins, B.S.; Hayman, J.A.; Jaiyesimi, I.; Jampol, L.M.; et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. *Arch. Ophthalmol.* **2005**, *123*, 1639–1643. [[CrossRef](#)] [[PubMed](#)]
- Refaian, N.; Schlereth, S.L.; Koch, K.R.; Notara, M.; Hos, D.; Mescher, M.; Iden, S.; Bosch, J.J.; Jager, M.J.; Cursiefen, C.; et al. Comparing the Hem- and Lymphangiogenic Profile of Conjunctival and Uveal Melanoma Cell Lines. *Investig. Ophthalmol. Vis. Sci.* **2015**, *56*, 5691–5697. [[CrossRef](#)]
- Heindl, L.M.; Hofmann, T.N.; Adler, W.; Knorr, H.L.; Holbach, L.M.; Naumann, G.O.; Kruse, F.E.; Cursiefen, C. Intraocular tumor-associated lymphangiogenesis a novel prognostic factor for ciliary body melanomas with extraocular extension? *Ophthalmology* **2010**, *117*, 334–342. [[CrossRef](#)] [[PubMed](#)]

21. Kujala, E.; Tuomaala, S.; Eskelin, S.; Kivela, T. Mortality after uveal and conjunctival melanoma: Which tumour is more deadly? *Acta Ophthalmol.* **2009**, *87*, 149–153. [[CrossRef](#)] [[PubMed](#)]
22. Van Beek, J.G.; Koopmans, A.E.; Vaarwater, J.; de Rooij, J.J.; Paridaens, D.; Naus, N.C.; de Klein, A.; Verdijk, R.M.; Kilic, E. The prognostic value of extraocular extension in relation to monosomy 3 and gain of chromosome 8q in uveal melanoma. *Investig. Ophthalmol. Vis. Sci.* **2014**, *55*, 1284–1291. [[CrossRef](#)]
23. Van Beek, J.G.M.; van den Bosch, Q.C.C.; Naus, N.; Paridaens, D.; de Klein, A.; Kilic, E.; Verdijk, R.M. Absence of Intraocular Lymphatic Vessels in Uveal Melanomas with Extrascleral Growth. *Cancers* **2019**, *11*, 228. [[CrossRef](#)] [[PubMed](#)]
24. Grisanti, S.; Tura, A. Uveal Melanoma. In *Noncutaneous Melanoma*; Scott, J.F., Gerstenblith, M.R., Eds.; Codon Publications: Brisbane, Australia, 2018.
25. Li, Y.; Shi, J.; Yang, J.; Ge, S.; Zhang, J.; Jia, R.; Fan, X. Uveal melanoma: Progress in molecular biology and therapeutics. *Ther. Adv. Med. Oncol.* **2020**, *12*, 1758835920965852. [[CrossRef](#)] [[PubMed](#)]
26. Lipski, A.C.; Lakotka, N.; Riechardt, A.I.; Willerding, G.D.; Heufelder, J.; Turkmen, S.; Keilholz, U.; Moser, L.; Jousen, A.M. Diagnosis of and therapy for choroidal melanoma. *Klin. Monbl. Augenheilkd.* **2013**, *230*, 1005–1019. [[CrossRef](#)]
27. LeBleu, V.S. Imaging the Tumor Microenvironment. *Cancer J.* **2015**, *21*, 174–178. [[CrossRef](#)] [[PubMed](#)]
28. Wan, G.Y.; Liu, Y.; Chen, B.W.; Liu, Y.Y.; Wang, Y.S.; Zhang, N. Recent advances of sonodynamic therapy in cancer treatment. *Cancer Biol. Med.* **2016**, *13*, 325–338. [[CrossRef](#)] [[PubMed](#)]
29. Hanahan, D.; Weinberg, R.A. The hallmarks of cancer. *Cell* **2000**, *100*, 57–70. [[CrossRef](#)]
30. Tirosh, I.; Izar, B.; Prakadan, S.M.; Wadsworth, M.H., 2nd; Treacy, D.; Trombetta, J.J.; Rotem, A.; Rodman, C.; Lian, C.; Murphy, G.; et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. *Science* **2016**, *352*, 189–196. [[CrossRef](#)] [[PubMed](#)]
31. Lambrechts, D.; Wauters, E.; Boeckx, B.; Aibar, S.; Nittner, D.; Burton, O.; Bassez, A.; Decaluwe, H.; Pircher, A.; Van den Eynde, K.; et al. Phenotype molding of stromal cells in the lung tumor microenvironment. *Nat. Med.* **2018**, *24*, 1277–1289. [[CrossRef](#)]
32. Wagner, J.; Rapsomaniki, M.A.; Chevrier, S.; Anzeneder, T.; Langwieder, C.; Dykgers, A.; Rees, M.; Ramaswamy, A.; Muenst, S.; Soysal, S.D.; et al. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. *Cell* **2019**, *177*, 1330–1345.e1318. [[CrossRef](#)] [[PubMed](#)]
33. Villadolid, J.; Amin, A. Immune checkpoint inhibitors in clinical practice: Update on management of immune-related toxicities. *Transl. Lung Cancer Res.* **2015**, *4*, 560–575. [[CrossRef](#)] [[PubMed](#)]
34. Darvin, P.; Toor, S.M.; Sasidharan Nair, V.; Elkord, E. Immune checkpoint inhibitors: Recent progress and potential biomarkers. *Exp. Mol. Med.* **2018**, *50*, 1–11. [[CrossRef](#)] [[PubMed](#)]
35. Luke, J.J.; Callahan, M.K.; Postow, M.A.; Romano, E.; Ramaiya, N.; Bluth, M.; Giobbie-Hurder, A.; Lawrence, D.P.; Ibrahim, N.; Ott, P.A.; et al. Clinical activity of ipilimumab for metastatic uveal melanoma: A retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. *Cancer* **2013**, *119*, 3687–3695. [[CrossRef](#)]
36. Heppt, M.V.; Steeb, T.; Schlager, J.G.; Rosumeck, S.; Dressler, C.; Ruzicka, T.; Nast, A.; Berking, C. Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review. *Cancer Treat. Rev.* **2017**, *60*, 44–52. [[CrossRef](#)]
37. Algazi, A.P.; Tsai, K.K.; Shoushtari, A.N.; Munhoz, R.R.; Eroglu, Z.; Piulats, J.M.; Ott, P.A.; Johnson, D.B.; Hwang, J.; Daud, A.I.; et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. *Cancer* **2016**, *122*, 3344–3353. [[CrossRef](#)]
38. Maruhashi, T.; Sugiura, D.; Okazaki, I.M.; Okazaki, T. LAG-3: From molecular functions to clinical applications. *J. Immunother. Cancer* **2020**, *8*, e001014. [[CrossRef](#)]
39. Huo, J.L.; Wang, Y.T.; Fu, W.J.; Lu, N.; Liu, Z.S. The promising immune checkpoint LAG-3 in cancer immunotherapy: From basic research to clinical application. *Front. Immunol.* **2022**, *13*, 956090. [[CrossRef](#)]
40. Ruffo, E.; Wu, R.C.; Bruno, T.C.; Workman, C.J.; Vignali, D.A.A. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. *Semin. Immunol.* **2019**, *42*, 101305. [[CrossRef](#)]
41. Puhr, H.C.; Ilhan-Mutlu, A. New emerging targets in cancer immunotherapy: The role of LAG3. *ESMO Open* **2019**, *4*, e000482. [[CrossRef](#)] [[PubMed](#)]
42. Shi, A.P.; Tang, X.Y.; Xiong, Y.L.; Zheng, K.F.; Liu, Y.J.; Shi, X.G.; Lv, Y.; Jiang, T.; Ma, N.; Zhao, J.B. Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer. *Front. Immunol.* **2021**, *12*, 785091. [[CrossRef](#)]
43. Soury, Z.; Wierenga, A.P.A.; Kroes, W.G.M.; van der Velden, P.A.; Verdijk, R.M.; Eikmans, M.; Luyten, G.P.M.; Jager, M.J. LAG3 and Its Ligands Show Increased Expression in High-Risk Uveal Melanoma. *Cancers* **2021**, *13*, 4445. [[CrossRef](#)] [[PubMed](#)]
44. Kouo, T.; Huang, L.; Pucsek, A.B.; Cao, M.; Solt, S.; Armstrong, T.; Jaffee, E. Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells. *Cancer Immunol. Res.* **2015**, *3*, 412–423. [[CrossRef](#)] [[PubMed](#)]
45. Xu, F.; Liu, J.; Liu, D.; Liu, B.; Wang, M.; Hu, Z.; Du, X.; Tang, L.; He, F. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. *Cancer Res.* **2014**, *74*, 3418–3428. [[CrossRef](#)] [[PubMed](#)]
46. Shields, C.L.; Furuta, M.; Thangappan, A.; Nagori, S.; Mashayekhi, A.; Lally, D.R.; Kelly, C.C.; Rudich, D.S.; Nagori, A.V.; Wakade, O.A.; et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. *Arch. Ophthalmol.* **2009**, *127*, 989–998. [[CrossRef](#)]

47. Diener-West, M.; Hawkins, B.S.; Markowitz, J.A.; Schachat, A.P. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. *Arch. Ophthalmol.* **1992**, *110*, 245–250. [[CrossRef](#)]
48. McLean, I.W.; Foster, W.D.; Zimmerman, L.E.; Gamel, J.W. Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. *Am. J. Ophthalmol.* **1983**, *96*, 502–509. [[CrossRef](#)]
49. Gamel, J.W.; McLean, I.W.; Foster, W.D.; Zimmerman, L.E. Uveal melanomas: Correlation of cytologic features with prognosis. *Cancer* **1978**, *41*, 1897–1901. [[CrossRef](#)]
50. Seddon, J.M.; Polivogianis, L.; Hsieh, C.C.; Albert, D.M.; Gamel, J.W.; Gragoudas, E.S. Death from uveal melanoma. Number of epithelioid cells and inverse SD of nucleolar area as prognostic factors. *Arch. Ophthalmol.* **1987**, *105*, 801–806. [[CrossRef](#)]
51. Seregard, S.; Kock, E. Prognostic indicators following enucleation for posterior uveal melanoma. A multivariate analysis of long-term survival with minimized loss to follow-up. *Acta Ophthalmol. Scand.* **1995**, *73*, 340–344. [[CrossRef](#)]
52. Coupland, S.E.; Campbell, I.; Damato, B. Routes of extraocular extension of uveal melanoma: Risk factors and influence on survival probability. *Ophthalmology* **2008**, *115*, 1778–1785. [[CrossRef](#)]
53. Makitie, T.; Summanen, P.; Tarkkanen, A.; Kivela, T. Tumor-infiltrating macrophages (CD68(+)) cells and prognosis in malignant uveal melanoma. *Investig. Ophthalmol. Vis. Sci.* **2001**, *42*, 1414–1421.
54. Shabo, I.; Stal, O.; Olsson, H.; Dore, S.; Svanvik, J. Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. *Int. J. Cancer* **2008**, *123*, 780–786. [[CrossRef](#)]
55. Kawamura, K.; Komohara, Y.; Takaishi, K.; Katabuchi, H.; Takeya, M. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. *Pathol. Int.* **2009**, *59*, 300–305. [[CrossRef](#)] [[PubMed](#)]
56. Shabo, I.; Olsson, H.; Sun, X.F.; Svanvik, J. Expression of the macrophage antigen CD163 in rectal cancer cells is associated with early local recurrence and reduced survival time. *Int. J. Cancer* **2009**, *125*, 1826–1831. [[CrossRef](#)] [[PubMed](#)]
57. Kurahara, H.; Shinchi, H.; Mataka, Y.; Maemura, K.; Noma, H.; Kubo, F.; Sakoda, M.; Ueno, S.; Natsugoe, S.; Takao, S. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. *J. Surg. Res.* **2011**, *167*, e211–e219. [[CrossRef](#)] [[PubMed](#)]
58. Mills, C.D.; Kincaid, K.; Alt, J.M.; Heilman, M.J.; Hill, A.M. M-1/M-2 macrophages and the Th1/Th2 paradigm. *J. Immunol.* **2000**, *164*, 6166–6173. [[CrossRef](#)]
59. Sica, A.; Schioppa, T.; Mantovani, A.; Allavena, P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: Potential targets of anti-cancer therapy. *Eur. J. Cancer* **2006**, *42*, 717–727. [[CrossRef](#)]
60. Guruvayoorappan, C. Tumor versus tumor-associated macrophages: How hot is the link? *Integr. Cancer Ther.* **2008**, *7*, 90–95. [[CrossRef](#)]
61. Bronkhorst, I.H.; Ly, L.V.; Jordanova, E.S.; Vrolijk, J.; Versluis, M.; Luyten, G.P.; Jager, M.J. Detection of M2-macrophages in uveal melanoma and relation with survival. *Investig. Ophthalmol. Vis. Sci.* **2011**, *52*, 643–650. [[CrossRef](#)] [[PubMed](#)]
62. Mantovani, A.; Locati, M. Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: Lessons and open questions. *Arterioscler. Thromb. Vasc. Biol.* **2013**, *33*, 1478–1483. [[CrossRef](#)] [[PubMed](#)]
63. Zeisberger, S.M.; Odermatt, B.; Marty, C.; Zehnder-Fjallman, A.H.; Ballmer-Hofer, K.; Schwendener, R.A. Clodronate-liposome-mediated depletion of tumour-associated macrophages: A new and highly effective antiangiogenic therapy approach. *Br. J. Cancer* **2006**, *95*, 272–281. [[CrossRef](#)]
64. Gazzaniga, S.; Bravo, A.I.; Guglielmotti, A.; van Rooijen, N.; Maschi, F.; Vecchi, A.; Mantovani, A.; Mordoh, J.; Wainstok, R. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. *J. Invest. Dermatol.* **2007**, *127*, 2031–2041. [[CrossRef](#)]
65. Sabatino, R.; Antonelli, A.; Battistelli, S.; Schwendener, R.; Magnani, M.; Rossi, L. Macrophage depletion by free bisphosphonates and zoledronate-loaded red blood cells. *PLoS ONE* **2014**, *9*, e101260. [[CrossRef](#)]
66. Abrahamsen, B. Adverse effects of bisphosphonates. *Calcif. Tissue Int.* **2010**, *86*, 421–435. [[CrossRef](#)]
67. Vargas-Franco, J.W.; Castaneda, B.; Redini, F.; Gomez, D.F.; Heymann, D.; Lezot, F. Paradoxical side effects of bisphosphonates on the skeleton: What do we know and what can we do? *J. Cell. Physiol.* **2018**, *233*, 5696–5715. [[CrossRef](#)] [[PubMed](#)]
68. Nourinia, R.; Ahmadi, H.; Rezaei-Kanavi, M.; Shoeibi, N.; Kamrava, K.; Karimi, S. Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model. *J. Ophthalmic. Vis. Res.* **2014**, *9*, 44–49. [[PubMed](#)]
69. Koch, K.R.; Hishmi, A.M.; Ortmann, M.; Heindl, L.M. Uveal Melanoma Cell Seeding after Transretinal Tumor Biopsy? *Ocul. Oncol. Pathol.* **2017**, *3*, 164–167. [[CrossRef](#)] [[PubMed](#)]
70. Bergers, G.; Benjamin, L.E. Tumorigenesis and the angiogenic switch. *Nat. Rev. Cancer* **2003**, *3*, 401–410. [[CrossRef](#)] [[PubMed](#)]
71. Ribatti, D.; Nico, B.; Crivellato, E.; Roccaro, A.M.; Vacca, A. The history of the angiogenic switch concept. *Leukemia* **2007**, *21*, 44–52. [[CrossRef](#)] [[PubMed](#)]
72. Baeriswyl, V.; Christofori, G. The angiogenic switch in carcinogenesis. *Semin. Cancer Biol.* **2009**, *19*, 329–337. [[CrossRef](#)] [[PubMed](#)]
73. Schroedl, F.; Brehmer, A.; Neuhuber, W.L.; Kruse, F.E.; May, C.A.; Cursiefen, C. The normal human choroid is endowed with a significant number of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1)-positive macrophages. *Investig. Ophthalmol. Vis. Sci.* **2008**, *49*, 5222–5229. [[CrossRef](#)] [[PubMed](#)]
74. Heindl, L.M.; Hofmann, T.N.; Knorr, H.L.; Rummelt, C.; Schrodl, F.; Schlotzer-Schrehardt, U.; Holbach, L.M.; Naumann, G.O.; Kruse, F.E.; Cursiefen, C. Intraocular lymphangiogenesis in malignant melanomas of the ciliary body with extraocular extension. *Investig. Ophthalmol. Vis. Sci.* **2009**, *50*, 1988–1995. [[CrossRef](#)] [[PubMed](#)]

75. Kashyap, S.; Singh, M.K.; Kumar, N.; Jha, J.; Lomi, N.; Meel, R.; Bakhshi, S.; Sen, S.; Singh, L. Implications of LAG3 and CTLA4 immune checkpoints beyond PD-1/PD-L1 as a potential target in determining the prognosis of uveal melanoma patients. *Br. J. Ophthalmol.* **2023**. [[CrossRef](#)]
76. Durante, M.A.; Rodriguez, D.A.; Kurtenbach, S.; Kuznetsov, J.N.; Sanchez, M.I.; Decatur, C.L.; Snyder, H.; Feun, L.G.; Livingstone, A.S.; Harbour, J.W. Single-cell analysis reveals new evolutionary complexity in uveal melanoma. *Nat. Commun.* **2020**, *11*, 496. [[CrossRef](#)]
77. Wessely, A.; Steeb, T.; Erdmann, M.; Heinzerling, L.; Vera, J.; Schlaak, M.; Berking, C.; Heppt, M.V. The Role of Immune Checkpoint Blockade in Uveal Melanoma. *Int. J. Mol. Sci.* **2020**, *21*, 30879. [[CrossRef](#)] [[PubMed](#)]
78. Bol, K.F.; Ellebaek, E.; Hoejberg, L.; Bagger, M.M.; Larsen, M.S.; Klausen, T.W.; Kohler, U.H.; Schmidt, H.; Bastholt, L.; Kiilgaard, J.F.; et al. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. *Cancers* **2019**, *11*, 1489. [[CrossRef](#)]
79. Singh, L.; Singh, M.K.; Kenney, M.C.; Jager, M.J.; Rizvi, M.A.; Meel, R.; Lomi, N.; Bakhshi, S.; Sen, S.; Kashyap, S. Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: Correlation with tumor-infiltrating lymphocytes and clinicopathological parameters. *Cancer Immunol. Immunother.* **2021**, *70*, 1291–1303. [[CrossRef](#)]
80. De Vos, L.; Carrillo Cano, T.M.; Zarbl, R.; Klumper, N.; Ralser, D.J.; Franzen, A.; Herr, E.; Gabrielpillai, J.; Vogt, T.J.; Dietrich, J.; et al. CTLA4, PD-1, PD-L1, PD-L2, TIM-3, TIGIT, and LAG3 DNA Methylation Is Associated With BAP1 -Aberrancy, Transcriptional Activity, and Overall Survival in Uveal Melanoma. *J. Immunother.* **2022**, *45*, 324–334. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

4. Diskussion

Die vorliegende Arbeit ist die erste Untersuchung zur Zusammensetzung des Tumor Microenvironments des uvealen Melanoms im Hinblick auf die Lokalisierung innerhalb des Tumors und innerhalb des Auges. Das entsprechende Studiendesign wurde im Teil „Methoden“ ausführlich dargelegt.

Es fanden sich unter anderem die folgenden relevanten Ergebnisse:

- Blutgefäße sind hauptsächlich in der Mitte des Tumors lokalisiert, während LYVE1-immunpositive Zellen (Lymphendothelzellen) und Immunzellen hauptsächlich im äußeren Bereich des Tumors zu finden sind.
- Im äußeren Bereich des Tumors nehmen CD68-immunpositive Makrophagen, CD3-immunpositive T-Lymphozyten und LYVE1-immunpositive Zellen mehr Fläche auf der Seite des Glaskörpers ein, als auf der Seite der Sklera.

4.1. Tumorcharakteristika

Die Studiengruppe umfasst 18 enukleierte Augen, wobei das mittlere Alter der Patienten bei Enukleation 69 Jahre betrug. Kürzlich wurde berichtet, dass die Mehrheit der uvealen Melanome in Deutschland Patienten über 65 Jahren betrifft³. Dies stimmt gut mit unseren Ergebnissen überein. Männliche und weibliche Patient*innen sind in unserer Studiengruppe gleichermaßen vertreten. Dies stimmt ebenfalls mit den Ergebnissen einer großen Studie über 8033 Augen mit uvealem Melanom von Shields et al. übereinstimmt⁴⁶.

Da der durchschnittliche Basaldurchmesser der von uns untersuchten Tumoren 17,21 mm mit einer durchschnittlichen Tumordicke von 7,37 mm betrug, sind alle unsere Schlussfolgerungen ausschließlich auf großflächige Tumoren zu beziehen. Die geschätzten 5-Jahres-Mortalitätsraten von Patienten mit uvealem Melanom mit großen Tumoren (Basaldurchmesser > 15 mm und Tumordicke > 8 mm) liegt deutlich höher (53 %), als von Patienten mit kleineren Tumoren (16 % für kleine Tumoren und 32 % für mittelgroße Tumoren)^{1,47}. Darüber hinaus zeigte Shields et al., dass jeder Millimeter Zunahme der Tumordicke mit einem etwa 5%-igen Risikoanstieg für das Auftreten von Metastasen innerhalb von 10 Jahren verbunden ist⁴⁶.

In der vorliegenden Studiengruppe wurde der Spindelzelltyp in 47 % der Fälle, der epitheloid-zellige Zelltyp in 13 % und der gemischte Zelltyp in 40 % der Fälle nachgewiesen. Der Tumorzelltyp ist ein wichtiger prognostischer Faktor beim uvealen Melanom. Das Callender-Klassifikationssystem unterteilt uveale Melanome in Spindel A, Spindel B, epitheloid und gemischte Tumoren⁴⁸. In mehreren Studien wurde nachgewiesen, dass das uveale Melanom des Spindelzelltyps die beste Prognose hat, während der epitheloidzellige Typ die schlechteste Prog-

nose aufweist⁴⁹⁻⁵². In unserer Studiengruppe stellte sich heraus, dass Tumoren des epitheloidzelligen Typs eine größere durchschnittliche Größe (20,5 mm) hatten, als solche des Spindelzelltyps (15,66 mm) oder des gemischten Zelltyps (17,66 mm). Es scheint also eine positive Korrelation zwischen der Menge der epitheloiden Zellen und dem Tumorwachstum zu geben, sodass uveale Melanome des epitheloiden oder gemischten Zelltyps mit größeren Tumoren einhergehen.

Die durchschnittliche von CD68-immunpositiven Makrophagen bedeckte Tumorfläche lag in dieser Studie bei 4,94 %. Hervorzuheben ist hier, dass die Durchschnittsfläche bei epitheloidzelligen Tumoren bei 8,97 %, beim Mischtyp bei 4,41 % und beim Spindelzelltyp bei 3,04 % lag. Makitie et al. fanden heraus, dass eine hohe Menge an tumorinfiltrierenden CD68-immunpositiven Makrophagen mit dem Vorhandensein von epitheloiden Zellen einhergeht⁵³. Die Ergebnisse der vorliegenden Arbeit stützen diese Erkenntnisse und es kann daraus geschlossen werden, dass die Menge an epitheloiden Zellen stark mit der Anzahl der CD68-immunpositiven Makrophagen und somit auch mit der Tumormalignität korreliert.

4.2. Makrophagen

Studien zu Makrophagen verschiedener maligner Krebsentitäten, beispielsweise zu Eierstocktumoren, Bauchspeicheldrüsen- und Brustkrebs, existieren bereits⁵⁴⁻⁵⁷. Je nach Makrophagentyp stellen sie entweder eine Verteidigung gegen Tumorzellen dar (M1-Typ) oder fördern die Tumorzellproliferation (M2-Typ). Es wurde nachgewiesen, dass tumorassoziierte Makrophagen hauptsächlich den M2-Phänotyp aufweisen und mit der Förderung von Tumorzellproliferation, Metastasierung und Angiogenese in Verbindung stehen⁵⁸⁻⁶². In der vorliegenden Studie konnte festgestellt werden, dass CD68-immunpositive Makrophagen einen großen Teil des Tumor Microenvironments ausmachen. Bronkehorst et al. haben gezeigt, dass die meisten Makrophagen beim uvealen Melanom dem M2-Typ angehören⁶¹. Basierend auf diesen Daten und der Erkenntnis, dass Makrophagen nach den Melanozyten die am häufigsten vorkommende Zellart sind, könnte die schwere Malignität des uvealen Melanoms auf die hohe Präsenz von M2-Makrophagen zurückzuführen sein. Folglich könnten Makrophagen als therapeutischer Angriffspunkt in der Behandlung von uvealen Melanomen zukünftig eine wichtige Rolle spielen.

Zusätzlich konnte der Nachweis erbracht werden, dass Makrophagen hauptsächlich im äußeren Bereich des Tumors lokalisiert sind. Da nachgewiesen wurde, dass M2-Makrophagen mit dem Tumorwachstum in Verbindung stehen, könnte es von Interesse sein, die Anzahl dieser Zellen zu vermindern oder sogar zu eliminieren. Bisphosphonate (z.B. liposome-encapsulated clodronate) zeigten in In-vitro- und In-vivo-Mausmodellen eine hohe Wirksamkeit bei der Depletion von Makrophagen⁶³⁻⁶⁵. Für die Makrophagen-Depletion wären hohe Dosen einer

systemischen Therapie notwendig, da die In-vivo-Wirksamkeit durch eine kurze Plasma-Halbwertszeit oder durch unveränderte Ausscheidung durch die Nieren begrenzt ist. Solch hohe Dosen sind beim Menschen aufgrund von Nephrotoxizität, Osteonekrose und Knochenbrüchen jedoch nicht anwendbar^{66,67}.

Aufgrund der vorrangigen Lokalisierung von Makrophagen im äußeren Bereich des uvealen Melanoms könnte eine intravitreale Injektion mit einem Bisphosphonat niedrigerer Dosierung eine effiziente therapeutische Option darstellen, um eine ausreichende lokale Dosis für die Makrophagen-Depletion zu erreichen. Dies könnte das Tumorwachstum stoppen und zu einer Verkleinerung des Tumors führen, wodurch er empfänglicher für Thermo-, Photodynamik- oder Strahlentherapie würde. In einer Studie an 20 Augen 20 pigmentierter Ratten zeigten Nourinia et al., dass bis zu 8 µg intravitrealer Zoledronsäure in Rattenaugen unbedenklich zu sein scheinen⁶⁸. Die nächsten Schritte zur Erforschung dieses neuen therapeutischen Ansatzes wären die Ermittlung des am besten geeigneten Bisphosphonats, der notwendigen Dosis für die Makrophagen-Depletion und die maximal anwendbare In-vivo-Dosis am menschlichen Auge. Eine Bisphosphonat-Injektion in den Tumor selbst ist nicht in Betracht zu ziehen, da dies eine Zellaussaat innerhalb des Auges zur Folge haben könnte⁶⁹.

4.3. Blutendothelzellen

Eine zentrale Erkenntnis ergibt sich aus der überwiegenden Lokalisierung von Blutendothelzellen im mittleren Teil des Tumors. Generell erfolgt in frühen Tumorstadien ein hyperplastisches Wachstum. Erreicht der Tumor eine kritische Größe, können vorbestehende Blutgefäße nicht mehr genügend Sauerstoff und Nährstoffe bereitstellen. Dies beeinträchtigt das weitere Tumorwachstum, allerdings können Tumorzellen diese Stagnation umgehen, indem sie die Tumorangiogenese induzieren. Der Übergang von anfänglicher Hyperplasie zum vaskularisierten bösartigen Tumorwachstum wurde von verschiedenen Autoren als "angiogenic switch" beschrieben und untersucht⁷⁰⁻⁷².

Tatsächlich spielt die Bildung von Blutgefäßen eine entscheidende Rolle in der Entwicklung und Differenzierung des Tumor Microenvironment. Die Beobachtung, dass Blutgefäße in uveal Melanomen hauptsächlich im Zentrum des Tumors lokalisiert sind, führt zu der Schlussfolgerung, dass die Bildung und Differenzierung des Tumor Microenvironments radiär verläuft, wodurch eine ausreichende Sauerstoff- und Nährstoffversorgung in allen Teilen des Tumors gewährleistet wird. Infolgedessen muss das Zentrum den am längsten existierenden Teil des Tumors repräsentieren, der folglich am meisten Zeit für die Angiogenese hatte, wodurch es hier zu einer erhöhten Gefäßdichte kommt. Die vorherrschende Lokalisierung der Blutgefäße im Tumorzentrum erschwert die äußere Behandlung des uveal Melanoms. Für Tumore kleiner Größe erfolgt dies durch transpupilläre Thermotherapie, photodynamische Therapie,

Plaque-Radiotherapie oder Protonentherapie, jedoch limitiert eine fortgeschrittene Tumorgroße den Erfolg dieser Therapien, was unter anderen auf die zentrale Lokalisation der Blutgefäße zurückzuführen ist.

4.4. Lymphendothelzellen

Epithelzellen und Lymphendothelzellen wurden von allen Zelltypen am wenigsten nachgewiesen. LYVE1-immunpositive Zellen wurden zudem hauptsächlich im äußeren Abschnitt des Tumors gefunden. LYVE1 wird nicht nur durch lymphatische Endothelzellen, sondern auch von Makrophagen und verschiedenen Strukturen des vorderen Augenabschnitts exprimiert^{23,73}. Darüber hinaus zeigte Schroedl et al. in einer Untersuchung an 17 physiologischen Augen, dass die erwachsene menschliche Aderhaut keine typischen lymphatischen Gefäße enthält, sondern eine signifikante Menge an LYVE1-immunpositiven Makrophagen⁷³. Aufgrund der geringen Menge an LYVE1-immunpositiven Zellen und der gleichen vorherrschenden Lokalisierung, die für CD68-immunpositive Makrophagen festgestellt wurde, ist die Struktur dieser Zellen als lymphatische Gefäße in Frage zu stellen. Für den Fall, dass diese Strukturen keine lymphatischen Gefäße wären, würde dies verschiedene Studien unterstützen, die intraokulare lymphatische Strukturen beim uvealen Melanom nicht nachweisen konnten^{19,20,23,74}.

4.5. Immuncheckpoints und Checkpoint-Inhibitoren

Die Analyse von LAG-3 und seinen Liganden zeigte eine hohe Repräsentation von Galectin-3 und LAG-3, wohingegen LSECTin kaum nachgewiesen wurde. Kashyap et al. stellten fest, dass hohe LAG-3-Werte beim uvealen Melanom mit anderen Hochrisikoparametern und einem hohen metastatischen Potenzial assoziiert sind. Die fortgeschrittenen Tumorgroßen der Studiengruppe in Kombination mit der hohen Repräsentation von LAG-3 unterstützen diese Beobachtung⁷⁵. Darüber hinaus gehen die Ergebnisse mit der Annahme von Souri et al. einher, dass LAG-3 und Galectin-3 in uvealen Melanomen stark interagieren. Es ist bekannt, dass Galectin-3 LAG-3 an CD8-positiven T-Zellen bindet. Daher könnte die LAG-3/Galectin-3-Interaktion beim uvealen Melanom zu einer reduzierten Aktivität der CD8-positiven T-Zellen führen⁴³. Durante et al. identifizierten LAG-3 als den dominantesten Immuncheckpoint beim uvealen Melanom⁷⁶. In der hier vorliegenden Arbeit waren LAG-3 und Galectin-3 gleichermaßen repräsentiert.

Therapien auf der Basis von Immuncheckpoint-Inhibitoren sind ein moderner und vielversprechender Ansatz zur Behandlung verschiedener solider Tumoren, einschließlich des metastasierten kutanen Melanoms. Im Gegensatz dazu zeigte das uveale Melanom bisweilen ein schlechtes Ansprechen auf Checkpoint-Immuntherapien, wie beispielsweise auf CTLA-4 (cytotoxic T-lymphocyte antigen 4) und PD-1 (programmed cell death protein 1).^{33-35,37,77,78} Hohe Expression von PD-1 und PD-L1 (programmed cell death-ligand 1) und das Vorhandensein

von tumorinfiltrierenden Lymphozyten sind jedoch mit Parametern für eine schlechte Prognose assoziiert, wie dem Verlust von BAP-1, dem epitheloiden Zelltyp und Lebermetastasen ⁷⁹. Ebenso wurde gezeigt, dass die Methylierung von Immuncheckpoint-Genen, wie CTLA4, PD-1, PD-L1 und LAG-3 stark mit dem BAP1-Mutationsstatus und dem Gesamtüberleben beim uvealen Melanom korreliert. Folglich sollten DNA-Methylierungstests für Immuncheckpoint-Gene als prädiktive Biomarker für die Reaktion auf Immuntherapie etabliert werden ⁸⁰.

4.6. Limitationen der Forschungsarbeit und Ausblick

Die Analyse der durchschnittlichen Fläche, welche von den untersuchten Zelltypen abgedeckt wurde, ergab, dass im Durchschnitt 13 % der Gesamtfläche des Tumors erfasst wurden. Es ist offensichtlich, dass das Tumor Microenvironment aus noch weiteren Zelltypen und -untertypen, sowie aus nichtzellulären Verbindungen besteht, die nicht vollständig durch das in dieser Studie angewendete Marker-Panel erfasst werden konnten. Darüber hinaus ist zu beachten, dass die präsentierten Ergebnisse aus zweidimensionalen Tumorschnitten stammen, während der Tumor selbst ein komplexes dreidimensionales Gebilde ist.

Aus der vorliegenden Studie gingen bemerkenswerte Unterschiede in der Lokalisation und im Auftreten verschiedener Zelltypen des Tumor Microenvironments des uvealen Melanoms hervor. Basierend auf diesen Ergebnissen werden eine größere Studiengruppe, ein erweitertes Marker-Panel und präklinische Studien benötigt, um die Ergebnisse zu untermauern und neue Behandlungsansätze zu erforschen.

5. Literaturverzeichnis

1. Kaliki S, Shields CL. Uveal melanoma: relatively rare but deadly cancer. *Eye (Lond)* 2017; **31**(2): 241-57.
2. McLaughlin CC, Wu XC, Jemal A, Martin HJ, Roche LM, Chen VW. Incidence of noncutaneous melanomas in the U.S. *Cancer* 2005; **103**(5): 1000-7.
3. Mor JM, Rokohl AC, Dahm S, Kraywinkel K, Heindl LM. Epidemiology of uveal melanomas in Germany. *Acta Ophthalmol* 2021.
4. Aronow ME, Topham AK, Singh AD. Uveal Melanoma: 5-Year Update on Incidence, Treatment, and Survival (SEER 1973-2013). *Ocul Oncol Pathol* 2018; **4**(3): 145-51.
5. Singh AD, Turell ME, Topham AK. Uveal melanoma: trends in incidence, treatment, and survival. *Ophthalmology* 2011; **118**(9): 1881-5.
6. Virgili G, Gatta G, Ciccolallo L, et al. Incidence of uveal melanoma in Europe. *Ophthalmology* 2007; **114**(12): 2309-15.
7. Jager MJ, Shields CL, Cebulla CM, et al. Uveal melanoma. *Nat Rev Dis Primers* 2020; **6**(1): 24.
8. Grisanti S, Ranjbar M, Tura A, Heindl LM, Kakkassery V. [Uveal melanoma : Early detection as the key to successful personalized medicine]. *Ophthalmologe* 2020; **117**(6): 508-20.
9. Hoiom V, Edsgard D, Helgadottir H, et al. Hereditary uveal melanoma: a report of a germline mutation in BAP1. *Genes Chromosomes Cancer* 2013; **52**(4): 378-84.
10. Johansson P, Aoude LG, Wadt K, et al. Deep sequencing of uveal melanoma identifies a recurrent mutation in PLCB4. *Oncotarget* 2016; **7**(4): 4624-31.
11. Royer-Bertrand B, Torsello M, Rimoldi D, et al. Comprehensive Genetic Landscape of Uveal Melanoma by Whole-Genome Sequencing. *Am J Hum Genet* 2016; **99**(5): 1190-8.
12. Van Raamsdonk CD, Bezrookove V, Green G, et al. Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi. *Nature* 2009; **457**(7229): 599-602.
13. Van Raamsdonk CD, Griewank KG, Crosby MB, et al. Mutations in GNA11 in uveal melanoma. *N Engl J Med* 2010; **363**(23): 2191-9.
14. Damato B, Dopierala J, Klaasen A, van Dijk M, Sibbring J, Coupland SE. Multiplex ligation-dependent probe amplification of uveal melanoma: correlation with metastatic death. *Invest Ophthalmol Vis Sci* 2009; **50**(7): 3048-55.
15. Prescher G, Bornfeld N, Hirche H, Horsthemke B, Jockel KH, Becher R. Prognostic implications of monosomy 3 in uveal melanoma. *Lancet* 1996; **347**(9010): 1222-5.
16. Scholes AG, Damato BE, Nunn J, Hiscott P, Grierson I, Field JK. Monosomy 3 in uveal melanoma: correlation with clinical and histologic predictors of survival. *Invest Ophthalmol Vis Sci* 2003; **44**(3): 1008-11.
17. Shields CL, Ganguly A, Bianciotto CG, Turaka K, Tavallali A, Shields JA. Prognosis of uveal melanoma in 500 cases using genetic testing of fine-needle aspiration biopsy specimens. *Ophthalmology* 2011; **118**(2): 396-401.
18. Diener-West M, Reynolds SM, Agugliaro DJ, et al. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group Report No. 26. *Arch Ophthalmol* 2005; **123**(12): 1639-43.
19. Refaian N, Schlereth SL, Koch KR, et al. Comparing the Hem- and Lymphangiogenic Profile of Conjunctival and Uveal Melanoma Cell Lines. *Invest Ophthalmol Vis Sci* 2015; **56**(9): 5691-7.
20. Heindl LM, Hofmann TN, Adler W, et al. Intraocular tumor-associated lymphangiogenesis a novel prognostic factor for ciliary body melanomas with extraocular extension? *Ophthalmology* 2010; **117**(2): 334-42.
21. Kujala E, Tuomaala S, Eskelin S, Kivela T. Mortality after uveal and conjunctival melanoma: which tumour is more deadly? *Acta Ophthalmol* 2009; **87**(2): 149-53.
22. van Beek JG, Koopmans AE, Vaarwater J, et al. The prognostic value of extraocular extension in relation to monosomy 3 and gain of chromosome 8q in uveal melanoma. *Invest Ophthalmol Vis Sci* 2014; **55**(3): 1284-91.

23. van Beek JGM, van den Bosch QCC, Naus N, et al. Absence of Intraocular Lymphatic Vessels in Uveal Melanomas with Extrascleral Growth. *Cancers (Basel)* 2019; **11**(2).
24. Grisanti S, Tura A. Uveal Melanoma. In: Scott JF, Gerstenblith MR, eds. *Noncutaneous Melanoma*. Brisbane (AU); 2018.
25. Li Y, Shi J, Yang J, et al. Uveal melanoma: progress in molecular biology and therapeutics. *Ther Adv Med Oncol* 2020; **12**: 1758835920965852.
26. Lipski AC, Lakotka N, Riechardt AI, et al. [Diagnosis of and therapy for choroidal melanoma]. *Klin Monbl Augenheilkd* 2013; **230**(10): 1005-19.
27. LeBleu VS. Imaging the Tumor Microenvironment. *Cancer J* 2015; **21**(3): 174-8.
28. Wan GY, Liu Y, Chen BW, Liu YY, Wang YS, Zhang N. Recent advances of sonodynamic therapy in cancer treatment. *Cancer Biol Med* 2016; **13**(3): 325-38.
29. Hanahan D, Weinberg RA. The hallmarks of cancer. *Cell* 2000; **100**(1): 57-70.
30. Tirosh I, Izar B, Prakadan SM, et al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq. *Science* 2016; **352**(6282): 189-96.
31. Lambrechts D, Wauters E, Boeckx B, et al. Phenotype molding of stromal cells in the lung tumor microenvironment. *Nat Med* 2018; **24**(8): 1277-89.
32. Wagner J, Rapsomaniki MA, Chevrier S, et al. A Single-Cell Atlas of the Tumor and Immune Ecosystem of Human Breast Cancer. *Cell* 2019; **177**(5): 1330-45 e18.
33. Villadolid J, Amin A. Immune checkpoint inhibitors in clinical practice: update on management of immune-related toxicities. *Transl Lung Cancer Res* 2015; **4**(5): 560-75.
34. Darvin P, Toor SM, Sasidharan Nair V, Elkord E. Immune checkpoint inhibitors: recent progress and potential biomarkers. *Exp Mol Med* 2018; **50**(12): 1-11.
35. Luke JJ, Callahan MK, Postow MA, et al. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. *Cancer* 2013; **119**(20): 3687-95.
36. Heppt MV, Steeb T, Schlager JG, et al. Immune checkpoint blockade for unresectable or metastatic uveal melanoma: A systematic review. *Cancer Treat Rev* 2017; **60**: 44-52.
37. Algazi AP, Tsai KK, Shoushtari AN, et al. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. *Cancer* 2016; **122**(21): 3344-53.
38. Maruhashi T, Sugiura D, Okazaki IM, Okazaki T. LAG-3: from molecular functions to clinical applications. *J Immunother Cancer* 2020; **8**(2).
39. Huo JL, Wang YT, Fu WJ, Lu N, Liu ZS. The promising immune checkpoint LAG-3 in cancer immunotherapy: from basic research to clinical application. *Front Immunol* 2022; **13**: 956090.
40. Ruffo E, Wu RC, Bruno TC, Workman CJ, Vignali DAA. Lymphocyte-activation gene 3 (LAG3): The next immune checkpoint receptor. *Semin Immunol* 2019; **42**: 101305.
41. Pühr HC, Ilhan-Mutlu A. New emerging targets in cancer immunotherapy: the role of LAG3. *ESMO Open* 2019; **4**(2): e000482.
42. Shi AP, Tang XY, Xiong YL, et al. Immune Checkpoint LAG3 and Its Ligand FGL1 in Cancer. *Front Immunol* 2021; **12**: 785091.
43. Souiri Z, Wierenga APA, Kroes WGM, et al. LAG3 and Its Ligands Show Increased Expression in High-Risk Uveal Melanoma. *Cancers (Basel)* 2021; **13**(17).
44. Kouo T, Huang L, Pucsek AB, et al. Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells. *Cancer Immunol Res* 2015; **3**(4): 412-23.
45. Xu F, Liu J, Liu D, et al. LSECtin expressed on melanoma cells promotes tumor progression by inhibiting antitumor T-cell responses. *Cancer Res* 2014; **74**(13): 3418-28.
46. Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. *Arch Ophthalmol* 2009; **127**(8): 989-98.
47. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. *Arch Ophthalmol* 1992; **110**(2): 245-50.
48. McLean IW, Foster WD, Zimmerman LE, Gamel JW. Modifications of Callender's classification of uveal melanoma at the Armed Forces Institute of Pathology. *Am J Ophthalmol* 1983; **96**(4): 502-9.

49. Gamel JW, McLean IW, Foster WD, Zimmerman LE. Uveal melanomas: correlation of cytologic features with prognosis. *Cancer* 1978; **41**(5): 1897-901.
50. Seddon JM, Polivogianis L, Hsieh CC, Albert DM, Gamel JW, Gragoudas ES. Death from uveal melanoma. Number of epithelioid cells and inverse SD of nucleolar area as prognostic factors. *Arch Ophthalmol* 1987; **105**(6): 801-6.
51. Seregard S, Kock E. Prognostic indicators following enucleation for posterior uveal melanoma. A multivariate analysis of long-term survival with minimized loss to follow-up. *Acta Ophthalmol Scand* 1995; **73**(4): 340-4.
52. Coupland SE, Campbell I, Damato B. Routes of extraocular extension of uveal melanoma: risk factors and influence on survival probability. *Ophthalmology* 2008; **115**(10): 1778-85.
53. Makitie T, Summanen P, Tarkkanen A, Kivela T. Tumor-infiltrating macrophages (CD68(+)) cells and prognosis in malignant uveal melanoma. *Invest Ophthalmol Vis Sci* 2001; **42**(7): 1414-21.
54. Shabo I, Stal O, Olsson H, Dore S, Svanvik J. Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival. *Int J Cancer* 2008; **123**(4): 780-6.
55. Kawamura K, Komohara Y, Takaishi K, Katabuchi H, Takeya M. Detection of M2 macrophages and colony-stimulating factor 1 expression in serous and mucinous ovarian epithelial tumors. *Pathol Int* 2009; **59**(5): 300-5.
56. Shabo I, Olsson H, Sun XF, Svanvik J. Expression of the macrophage antigen CD163 in rectal cancer cells is associated with early local recurrence and reduced survival time. *Int J Cancer* 2009; **125**(8): 1826-31.
57. Kurahara H, Shinci H, Mataka Y, et al. Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. *J Surg Res* 2011; **167**(2): e211-9.
58. Mills CD, Kincaid K, Alt JM, Heilman MJ, Hill AM. M-1/M-2 macrophages and the Th1/Th2 paradigm. *J Immunol* 2000; **164**(12): 6166-73.
59. Sica A, Schioppa T, Mantovani A, Allavena P. Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. *Eur J Cancer* 2006; **42**(6): 717-27.
60. Guruvayoorappan C. Tumor versus tumor-associated macrophages: how hot is the link? *Integr Cancer Ther* 2008; **7**(2): 90-5.
61. Bronkhorst IH, Ly LV, Jordanova ES, et al. Detection of M2-macrophages in uveal melanoma and relation with survival. *Invest Ophthalmol Vis Sci* 2011; **52**(2): 643-50.
62. Mantovani A, Locati M. Tumor-associated macrophages as a paradigm of macrophage plasticity, diversity, and polarization: lessons and open questions. *Arterioscler Thromb Vasc Biol* 2013; **33**(7): 1478-83.
63. Zeisberger SM, Odermatt B, Marty C, Zehnder-Fjallman AH, Ballmer-Hofer K, Schwendener RA. Clodronate-liposome-mediated depletion of tumour-associated macrophages: a new and highly effective antiangiogenic therapy approach. *Br J Cancer* 2006; **95**(3): 272-81.
64. Gazzaniga S, Bravo AI, Guglielmotti A, et al. Targeting tumor-associated macrophages and inhibition of MCP-1 reduce angiogenesis and tumor growth in a human melanoma xenograft. *J Invest Dermatol* 2007; **127**(8): 2031-41.
65. Sabatino R, Antonelli A, Battistelli S, Schwendener R, Magnani M, Rossi L. Macrophage depletion by free bisphosphonates and zoledronate-loaded red blood cells. *PLoS One* 2014; **9**(6): e101260.
66. Abrahamsen B. Adverse effects of bisphosphonates. *Calcif Tissue Int* 2010; **86**(6): 421-35.
67. Vargas-Franco JW, Castaneda B, Redini F, Gomez DF, Heymann D, Lezot F. Paradoxical side effects of bisphosphonates on the skeleton: What do we know and what can we do? *J Cell Physiol* 2018; **233**(8): 5696-715.
68. Nourinia R, Ahmadi H, Rezaei-Kanavi M, Shoeibi N, Kamrava K, Karimi S. Safety of Intravitreal Zoledronic Acid, an Anti-angiogenic Bisphosphonate, in a Rat Model. *J Ophthalmic Vis Res* 2014; **9**(1): 44-9.

69. Koch KR, Hishmi AM, Ortmann M, Heindl LM. Uveal Melanoma Cell Seeding after Transretinal Tumor Biopsy? *Ocul Oncol Pathol* 2017; **3**(3): 164-7.
70. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. *Nat Rev Cancer* 2003; **3**(6): 401-10.
71. Ribatti D, Nico B, Crivellato E, Roccaro AM, Vacca A. The history of the angiogenic switch concept. *Leukemia* 2007; **21**(1): 44-52.
72. Baeriswyl V, Christofori G. The angiogenic switch in carcinogenesis. *Semin Cancer Biol* 2009; **19**(5): 329-37.
73. Schroedl F, Brehmer A, Neuhuber WL, Kruse FE, May CA, Cursiefen C. The normal human choroid is endowed with a significant number of lymphatic vessel endothelial hyaluronate receptor 1 (LYVE-1)-positive macrophages. *Invest Ophthalmol Vis Sci* 2008; **49**(12): 5222-9.
74. Heindl LM, Hofmann TN, Knorr HL, et al. Intraocular lymphangiogenesis in malignant melanomas of the ciliary body with extraocular extension. *Invest Ophthalmol Vis Sci* 2009; **50**(5): 1988-95.
75. Kashyap S, Singh MK, Kumar N, et al. Implications of LAG3 and CTLA4 immune checkpoints beyond PD-1/PD-L1 as a potential target in determining the prognosis of uveal melanoma patients. *Br J Ophthalmol* 2023.
76. Durante MA, Rodriguez DA, Kurtenbach S, et al. Single-cell analysis reveals new evolutionary complexity in uveal melanoma. *Nat Commun* 2020; **11**(1): 496.
77. Wessely A, Steeb T, Erdmann M, et al. The Role of Immune Checkpoint Blockade in Uveal Melanoma. *Int J Mol Sci* 2020; **21**(3).
78. Bol KF, Ellebaek E, Hoejberg L, et al. Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma. *Cancers (Basel)* 2019; **11**(10).
79. Singh L, Singh MK, Kenney MC, et al. Prognostic significance of PD-1/PD-L1 expression in uveal melanoma: correlation with tumor-infiltrating lymphocytes and clinicopathological parameters. *Cancer Immunol Immunother* 2021; **70**(5): 1291-303.
80. de Vos L, Carrillo Cano TM, Zarbl R, et al. CTLA4 , PD-1 , PD-L1 , PD-L2 , TIM-3 , TIGIT , and LAG3 DNA Methylation Is Associated With BAP1 -Aberrancy, Transcriptional Activity, and Overall Survival in Uveal Melanoma. *J Immunother* 2022; **45**(7): 324-34.